

=> fil reg

FILE 'REGISTRY' ENTERED AT 16:17:53 ON 20 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 American Chemical Society (ACS)

STRUCTURE FILE UPDATES: 18 JUN 2002 HIGHEST RN 431976-32-8

DICTIONARY FILE UPDATES: 18 JUN 2002 HIGHEST RN 431976-32-8

TSCA INFORMATION NOW CURRENT THROUGH January 7, 2002

Please note that search-term pricing does apply when  
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Calculated physical property data is now available. See HELP PROPERTIES  
for more information. See STNote 27, Searching Properties in the CAS  
Registry File, for complete details:

<http://www.cas.org/ONLINE/STN/STNOTES/stnotes27.pdf>

=> d ide can tot

L78 ANSWER 1 OF 3 REGISTRY COPYRIGHT 2002 ACS

RN 53910-25-1 REGISTRY

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-  
pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-  
pentofuranosyl)-3,4,7,8-tetrahydro-, (R)-

OTHER NAMES:

CN 2'-Deoxycoformycin

CN CL 67310465

CN C1 825

CN Co-Vidarabine

CN Deoxycoformycin

CN Nipent

CN NSC 218321

CN Pentostatin

FS STEREOSEARCH

DR 59979-24-7, 63677-95-2, 69196-00-5, 70865-77-9

MF C11 H16 N4 O4


CI COM

LC STN Files: ADISINSIGHT, ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*,  
BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CBNB, CHEMLIST,  
CIN, DDFU, DIOGENES, DRUGNL, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, HSDB\*,  
IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE, MRCK\*, MSDS-OHS, NAPRALERT, PHAR,  
PROMT, RTECS\*, TOXCENTER, USAN, USPAT2, USPATFULL  
(\*File contains numerically searchable property data)

Other Sources: WHO

Absolute stereochemistry.

Jan Delaval  
Reference Librarian  
Biotechnology & Chemical Library  
CM1 1E07 - 703-308-4498  
[jan.delaval@uspto.gov](mailto:jan.delaval@uspto.gov)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

589 REFERENCES IN FILE CA (1967 TO DATE)  
 18 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
 589 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:363093  
 REFERENCE 2: 136:354224  
 REFERENCE 3: 136:323493  
 REFERENCE 4: 136:315004  
 REFERENCE 5: 136:304045  
 REFERENCE 6: 136:289052  
 REFERENCE 7: 136:257229  
 REFERENCE 8: 136:257222  
 REFERENCE 9: 136:247591  
 REFERENCE 10: 136:240866

L78 ANSWER 2 OF 3 REGISTRY COPYRIGHT 2002 ACS

RN 21679-14-1 REGISTRY

CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Adenine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (8CI)

OTHER NAMES:

CN 2-Fluoro-9-.beta.-D-arabinofuranosyladenine

CN 9-.beta.-D-Arabinofuranosyl-2-fluoroadenine

CN 9-.beta.-D-Arabinosyl-2-fluoroadenine

CN F-ara-A

CN Fludarabine

CN NSC 118218

CN NSC 118218H

FS STEREOSEARCH

MF C10 H12 F N5 O4


LC STN Files: ADISINSIGHT, ADISNEWS, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS, BIOTECHNO, CA, CANCERLIT, CAPLUS, CASREACT, CBNB, CHEMCATS, CHEMLIST, CIN, CSCHEM, DDFU, DIOGENES, DRUGPAT, DRUGU, DRUGUPDATES, EMBASE, IPA, MEDLINE, MRCK\*, PHAR, PROMT, RTECS\*, SYNTHLINE, TOXCENTER, USAN, USPATFULL

(\*File contains numerically searchable property data)

Other Sources: EINECS\*\*, WHO

(\*\*Enter CHEMLIST File for up-to-date regulatory information)

Absolute stereochemistry.



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

477 REFERENCES IN FILE CA (1967 TO DATE)

8 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA

482 REFERENCES IN FILE CAPLUS (1967 TO DATE)

REFERENCE 1: 136:384503

REFERENCE 2: 136:363356

REFERENCE 3: 136:350299

REFERENCE 4: 136:339000

REFERENCE 5: 136:334909

REFERENCE 6: 136:334908

REFERENCE 7: 136:315004

REFERENCE 8: 136:304045

REFERENCE 9: 136:303717

REFERENCE 10: 136:288681

L78 ANSWER 3 OF 3 REGISTRY COPYRIGHT 2002 ACS

RN 154-42-7 REGISTRY

CN 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI) (CA INDEX NAME)

OTHER CA INDEX NAMES:

CN Purine-6(1H)-thione, 2,3-dihydro-2-imino- (6CI)

CN Purine-6(1H)-thione, 2-amino- (7CI, 8CI)

CN Purine-6-thiol, 2-amino- (8CI)

OTHER NAMES:

CN 2-Amino-6-mercaptapurine

CN 2-Amino-9H-purine-6(1H)-thione

CN 2-Aminopurine-6-thiol

CN 6-Mercaptoguanine


CN 6-TG

CN 6-Thioguanine

CN Guanine, thio-

CN NSC 752

CN Tabloid  
CN Thioguanine  
CN Tioguanin  
CN Tioguanine  
FS 3D CONCORD  
DR 611-67-6, 1125-65-1, 1832-72-0, 5632-51-9  
MF C5 H5 N5 S  
CI COM  
LC STN Files: ADISNEWS, AGRICOLA, ANABSTR, BEILSTEIN\*, BIOBUSINESS, BIOSIS,  
BIOTECHNO, CA, CANCERLIT, CAOLD, CAPLUS, CASREACT, CEN, CHEMCATS,  
CHEMINFORMRX, CHEMLIST, CIN, CSCHEM, CSNB, DDFU, DIOGENES, DRUGU,  
EMBASE, GMELIN\*, HODOC\*, HSDB\*, IFICDB, IFIPAT, IFIUDB, IPA, MEDLINE,  
MRCK\*, NAPRALERT, NIOSHTIC, PIRA, PROMT, RTECS\*, TOXCENTER, USAN,  
USPAT2, USPATFULL  
(\*File contains numerically searchable property data)  
Other Sources: EINECS\*\*, WHO  
(\*\*Enter CHEMLIST File for up-to-date regulatory information)



\*\*PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT\*\*

1234 REFERENCES IN FILE CA (1967 TO DATE)  
54 REFERENCES TO NON-SPECIFIC DERIVATIVES IN FILE CA  
1240 REFERENCES IN FILE CAPLUS (1967 TO DATE)  
2 REFERENCES IN FILE CAOLD (PRIOR TO 1967)

REFERENCE 1: 136:380088  
REFERENCE 2: 136:379640  
REFERENCE 3: 136:350786  
REFERENCE 4: 136:334885  
REFERENCE 5: 136:318973  
REFERENCE 6: 136:318837  
REFERENCE 7: 136:318830  
REFERENCE 8: 136:315004  
REFERENCE 9: 136:304045  
REFERENCE 10: 136:299675

=> fil hcaplus

FILE 'HCAPLUS' ENTERED AT 16:17:59 ON 20 JUN 2002

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2002 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 20 Jun 2002 VOL 136 ISS 25  
FILE LAST UPDATED: 18 Jun 2002 (20020618/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

CAS roles have been modified effective December 16, 2001. Please check your SDI profiles to see if they need to be revised. For information on CAS roles, enter HELP ROLES at an arrow prompt or use the CAS Roles thesaurus (/RL field) in this file.

=> d all hitstr tot 177

L77 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2002 ACS  
AN 2002:335943 HCAPLUS  
TI HLA-haploidentical blood progenitor cell transplantation in osteopetrosis  
AU Schulz, Ansgar S.; Classen, Carl Friedrich; Mihatsch, Walther A.;  
Sigl-Kraetzig, Michael; Wiesneth, Markus; Debatin, Klaus-Michael;  
Friedrich, Wilhelm; Muller, Susanna M.  
CS Departments of Pediatrics and Transfusion Medicine, University of Ulm,  
Ulm, D-89075, Germany  
SO Blood (2002), 99(9), 3458-3460  
CODEN: BLOOAW; ISSN: 0006-4971  
PB American Society of Hematology  
DT Journal  
LA English  
CC 15-8 (Immunochemistry)  
Section cross-reference(s): 1  
AB Infantile osteopetrosis (OP) carries an extremely poor prognosis unless  
treated early by **hematopoietic** stem cell transplantation. We  
explored the use of purified blood progenitor cells from  
HLA-haploidentical parents in 7 patients lacking suitable matched donors.  
Blood progenitor cells were purified by pos. selection and by addnl.  
**T-cell** depletion using rosette formation. For  
conditioning, patients received busulfan, thiotepe, and either  
cyclophosphamide (5 patients) or **fludarabine** (2 patients).  
Stable donor engraftment developed in 6 of 7 patients. **Graft**  
**-vs.-host disease** was not obsd. Three of the 7  
patients had no major complications and 4 of 7 had both veno-occlusive  
**disease** and respiratory failure. Five of 7 patients survive with  
complete cure of OP at a median of 4 yr. Patients with OP lacking  
HLA-matched donors can be successfully treated by transplantation of  
purified blood progenitor cells from HLA-haploidentical donors.  
ST HLA progenitor cell transplant **graft host**  
**disease** osteopetrosis child  
IT Human  
Immunosuppressants  
(HLA-haploidentical blood progenitor cell transplantation in  
osteopetrosis)  
IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-haploidentical blood progenitor cell transplantation in

osteopetrosis)

IT **Transplant and Transplantation**  
(allotransplant; HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

IT Immunoglobulins  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(antithymocyte globulins; HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

IT Development, mammalian postnatal  
(child; HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

IT **Transplant and Transplantation**  
(graft-vs.-host reaction; HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

IT Bone, disease  
(osteopetrosis; HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

IT **Hematopoietic precursor cell**  
(stem; HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

IT 50-18-0, Cyclophosphamide 52-24-4, Thiotepe 55-98-1, Busulfan 21679-14-1, Fludarabine 140608-64-6, OKT-3  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

RE.CNT 16 THERE ARE 16 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE


- (1) Anasetti, C; N Engl J Med 1989, V17, P197
- (2) Aversa, F; J Clin Oncol 1999, V17, P1545 MEDLINE
- (3) Aversa, F; N Engl J Med 1998, V339, P1186 MEDLINE
- (4) Coccia, P; N Eng J Med 1980, V302, P701 MEDLINE
- (5) Fasth, A; Pediatr Transplant 1999, V3(suppl), P102
- (6) Felix, R; Eur J Endocrinol 1996, V134, P143 HCAPLUS
- (7) Fischer, A; Lancet 1990, V226, P850
- (8) Frattini, A; Nat Genet 2000, V25, P343 HCAPLUS
- (9) Friedrich, W; Eur J Pediatr 1965, V144, P125
- (10) Gerritsen, E; J Pediatr 1994, V125, P896 MEDLINE
- (11) Kornak, U; Cell 2001, V104, P205 HCAPLUS
- (12) Kornak, U; Hum Mol Genet 2000, V9, P2059 HCAPLUS
- (13) Mueller, S; Bone Marrow Transplant 1999, V24, P575
- (14) O'Reilly, R; Transplant Proc 1985, V17, P455
- (15) Reisner, Y; Blood 1983, V61, P341 MEDLINE
- (16) Wiesneth, M; Transfus Sci 1996, V17, P629 MEDLINE

IT **21679-14-1, Fludarabine**  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(HLA-haploidentical blood progenitor cell transplantation in osteopetrosis)

RN 21679-14-1 HCAPLUS

CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:198998 HCAPLUS

DN 136:353549

TI A cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation

AU Kean, Leslie S.; Durham, Megan M.; Adams, Andrew B.; Hsu, Lewis L.; Perry, Jennifer R.; Dillehay, Dirck; Pearson, Thomas C.; **Waller, Edmund K.**; Larsen, Christian P.; Archer, David R.

CS Division of Hematology, Oncology Blood and Marrow Transplantation, Department of Pediatrics, Emory University School of Medicine, Atlanta, GA, 30322, USA

SO Blood (2002), 99(5), 1840-1849

CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal

LA English

CC 14-6 (Mammalian Pathological Biochemistry)

AB The morbidity and mortality assocd. with sickle cell disease (SCD) is caused by hemolytic anemia, vaso-occlusion, and progressive multiorgan damage. Bone marrow transplantation (BMT) is currently the only curative therapy; however, toxic myeloablative preconditioning and barriers to allotransplantation limit this therapy to children with major SCD complications and HLA-matched donors. In trials of myeloablative BMT designed to yield total marrow replacement with donor stem cells, a subset of patients developed mixed chimerism. Importantly, these patients showed resolu. of SCD complications. This implies that less toxic preparative regimens, purposefully yielding mixed chimerism after transplantation, may be sufficient to cure SCD without the risks of myeloablation. To rigorously test this hypothesis, we used a murine model for SCD to investigate whether nonmyeloablative preconditioning coupled with tolerance induction could intentionally create mixed chimerism and a clin. cure. We applied a well-tolerated, nonirradn.-based, allogeneic transplantation protocol using nonmyeloablative preconditioning (low-dose busulfan) and costimulation blockade (CTLA4-Ig and anti-CD40L) to produce mixed chimerism and transplantation tolerance to fully major histocompatibility complex-mismatched donor marrow. Chimeric mice were phenotypically cured of SCD and had normal RBC morphol. and hematol. indexes (Hb, hematocrit, reticulocyte, and white blood cell counts) without evidence of graft vs. host disease. Importantly, they also showed normalization of characteristic spleen and kidney pathol. These expts. demonstrate the ability to produce a phenotypic cure for murine SCD using a nonmyeloablative protocol with fully histocompatibility complex-mismatched donors. They suggest a future treatment strategy for human SCD patients that reduces the toxicity of conventional BMT and expands the use of allotransplantation to non-HLA-matched donors.

ST sickle cell disease mixed chimerism MHC bone marrow transplantation

IT Histocompatibility antigens

- RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (MHC (major histocompatibility complex); cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation)
- IT **Transplant and Transplantation**  
 (bone marrow; cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation)
- IT Erythrocyte  
 Hematocrit  
**Immune tolerance**  
 Kidney  
 Leukocyte  
 Reticulocyte  
 Sickle cell anemia  
 Spleen  
 (cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation)
- IT Hemoglobins  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation)
- IT Bone marrow  
 (replacement; cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation)
- IT **Hematopoietic precursor cell**  
 (stem; cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation)
- IT Bone marrow  
 (transplant; cure for murine sickle cell disease through stable mixed chimerism and tolerance induction after nonmyeloablative conditioning and major histocompatibility complex-mismatched bone marrow transplantation)

RE.CNT 44 THERE ARE 44 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Adams, A; J Immunol 2001, V167, P1103 HCAPLUS
- (2) Akashi, K; Int J Hematol 1999, V69, P217 MEDLINE
- (3) Akashi, K; Nature 2000, V404, P193 HCAPLUS
- (4) Belcher, J; Blood 2000, V96, P2451 HCAPLUS
- (5) Bevers, E; Biol Chem 1998, V379, P973 HCAPLUS
- (6) Bill, J; J Exp Med 1989, V169, P1405 HCAPLUS
- (7) Bratton, D; J Biol Chem 1997, V272, P26159 HCAPLUS
- (8) Castro, O; Blood 1994, V84, P643 MEDLINE
- (9) Champlin, R; Curr Opin Oncol 1999, V11, P87 MEDLINE
- (10) Charache, S; N Engl J Med 1995, V332, P1317 MEDLINE
- (11) Christian, J; Exp Hematol 1996, V24, P82 MEDLINE
- (12) Closse, C; Br J Haematol 1999, V107, P300 HCAPLUS
- (13) Craddock, C; Curr Opin Hematol 1999, V6, P383 MEDLINE
- (14) Durham, M; J Immunol 2000, V165, P1 HCAPLUS
- (15) Dyson, P; Nature 1991, V349, P531 HCAPLUS
- (16) Frasc, S; J Biol Chem 2000, V275, P23065 HCAPLUS
- (17) Hoppe, C; Curr Opin Oncol 2001, V13, P85 MEDLINE
- (18) Iannone, R; Blood 2001, V97, P3960 HCAPLUS
- (19) Joneckis, C; Blood 1993, V82, P3548 MEDLINE
- (20) Kean, L; Blood 2000, V96, P598

- (21) Kinney, T; Pediatrics 1999, V103, P640 MEDLINE
- (22) Krishnamurti, L; N Engl J Med 2001, V344, P68 MEDLINE
- (23) Kuypers, F; Blood 1996, V87, P1179 HCAPLUS
- (24) Lyons, A; J Immunol Methods 1994, V171, P131 MEDLINE
- (25) Mentzer, W; Curr Opin Hematol 2000, V7, P95 MEDLINE
- (26) Miller, S; N Engl J Med 2000, V342, P83 MEDLINE
- (27) Nagel, R; Br J Haematol 2001, V112, P19 MEDLINE
- (28) Ohene-Frempong, K; Blood 1998, V91, P288 MEDLINE
- (29) Paszty, C; Science 1997, V278, P876 HCAPLUS
- (30) Platt, O; J Clin Invest 2000, V106, P337 HCAPLUS
- (31) Platt, O; N Engl J Med 1996, V335, P426 MEDLINE
- (32) Ryan, T; Science 1997, V278, P873 HCAPLUS
- (33) Salomon, B; Annu Rev Immunol 2001, V19, P225 HCAPLUS
- (34) Serke, S; Br J Haematol 1992, V81, P432 MEDLINE
- (35) Spitzer, T; Biol Blood Marrow Transplant 2000, V6, P309 MEDLINE
- (36) Swerlick, R; Blood 1993, V82, P1891 MEDLINE
- (37) Sykes, M; Nat Med 1997, V3, P783 HCAPLUS
- (38) Tomita, Y; J Immunol 1994, V153, P1087 HCAPLUS
- (39) Vermes, I; J Immunol Methods 1995, V184, P39 HCAPLUS
- (40) Vermylen, C; Bone Marrow Transplant 1998, V22, P1 MEDLINE
- (41) Walters, M; Biol Blood Marrow Transplant 1996, V2, P100 MEDLINE
- (42) Walters, M; Blood 2000, V95, P1918 HCAPLUS
- (43) Wekerle, T; J Exp Med 1998, V187, P2037 HCAPLUS
- (44) Wood, B; Blood 1996, V8, P1873

L77 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2002 ACS

AN 2002:102657 HCAPLUS

DN 136:272843

TI Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a nonmyeloablative conditioning regimen

AU Chakraverty, Ronjon; Peggs, Karl; Chopra, Rajesh; Milligan, Donald W.; Kottaridis, Panagiotis D.; Verfuerth, Stephanie; Geary, Johanne; Thuraisundaram, Dharsha; Branson, Kate; Chakrabarti, Suparno; Mahendra, Premini; Craddock, Charles; Parker, Anne; Hunter, Ann; Hale, Geoff; Waldmann, Herman; Williams, Catherine D.; Yong, Kwee; Linch, David C.; Goldstone, Anthony H.; MacKinnon, Stephen

CS Department of Haematology, University College London Hospital, London, WC1E 6HX, UK

SO Blood (2002), 99(3), 1071-1078

CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal

LA English

CC 1-6 (Pharmacology)

Section cross-reference(s): 15

AB A nonmyeloablative conditioning regimen was investigated in 47 patients with hematol. malignancy receiving **allogeneic** progenitor cells from matched, unrelated donors. The median patient age was 44 yr. The majority of patients had high-risk features, including having failed a prior transplantation (29 individuals). Twenty of the transplants were mismatched for HLA class I and/or class II alleles. Recipient conditioning consisted of 20 mg CAMPATH-1H on days -8 to -4, 30 mg/m<sup>2</sup> **fludarabine** on days -7 to -3, and 140 mg/m<sup>2</sup> melphalan on day -2.

**Graft-vs.-host disease (GVHD)**

prophylaxis was with cyclosporine A alone. Primary **graft** failure occurred in only 2 of 44 evaluable patients (4.5%). Chimerism studies in 34 patients indicated that the majority (85.3%) attained initial full donor chimerism. Only 3 patients developed grade III to IV acute **GVHD**, and no patients have yet developed chronic extensive **GVHD**. The estd. probability of nonrelapse mortality at day 100 was 14.9% (95% confidence interval [CI], 4.7%-25.1%). With a median follow-up of 344 days (range, 79-830), overall and progression-free survivals at 1 yr were 75.5% (95% CI, 62.8%-88.2%) and 61.5% (95% CI,

- 46.1%-76.8%), resp. In summary, a nonmyeloablative regimen incorporating in vivo CAMPATH-1H is effective in promoting durable engraftment in most patients and in reducing the risk of severe GVHD following matched unrelated donor transplantation.
- ST CAMPATH1H nonmyeloablative antitumor stem cell transplant hematol malignancy; unrelated donor nonmyeloablative conditioning MAb stem cell transplant rejection
- IT Human  
(CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-A; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-B; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-C; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Gene, animal  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-DQB1, antigen; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Gene, animal  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(HLA-DRB1, antigen; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT **Transplant and Transplantation**  
(**allotransplant**, bone marrow; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Bone marrow  
(**allotransplant**; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT **Transplant and Transplantation**  
(**graft-vs.-host** reaction; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Antitumor agents  
(hematol., CAMPATH-1H; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT Neoplasm  
(hematol.; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT **Cytomegalovirus**  
(infection reactivation; CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT 148-82-3, Melphalan 21679-14-1, Fludarabine 59865-13-3, Cyclosporine A 216503-57-0  
RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)
- IT 100-33-4, Pentamidine 8064-90-2, Cotrimoxazole 59277-89-3, Acyclovir 82410-32-0, Ganciclovir 84625-61-6, Itraconazole 86386-73-4, Fluconazole  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Bearman, S; J Clin Oncol 1989, V7, P1288 MEDLINE
- (2) Bertz, H; Leukemia 1997, V11, P281 MEDLINE
- (3) Broers, A; Blood 2000, V95, P2240 HCAPLUS
- (4) Champlin, R; Blood 2000, V95, P3996 HCAPLUS
- (5) Childs, R; Blood 1999, V94, P3234 HCAPLUS
- (6) Cornelissen, J; Blood 2001, V97, P1572 HCAPLUS
- (7) Einsele, H; Bone Marrow Transplant 2000, V25, P757 MEDLINE
- (8) Giralt, S; Blood 2001, V97, P631 HCAPLUS
- (9) Heitger, A; Blood 1997, V90, P850 HCAPLUS
- (10) Hurley, C; Hum Immunol 1999, V60, P347 MEDLINE
- (11) Khouri, I; J Clin Oncol 1998, V16, P2817 MEDLINE
- (12) Kolb, H; Blood 1990, V76, P2462 MEDLINE
- (13) Kottaridis, P; Blood 2000, V96, P2419 HCAPLUS
- (14) Labadie, J; Br J Haematol 1992, V80, P381 MEDLINE
- (15) Li, L; Mol Pharmacol 1997, V52, P798 HCAPLUS
- (16) Mackinnon, S; Blood 1994, V83, P3409 MEDLINE
- (17) Mandigers, C; Lancet 1998, V352, P1522 MEDLINE
- (18) McGlave, P; Blood 2000, V95, P2219 HCAPLUS
- (19) Petersdorf, E; Blood 1997, V89, P1818 HCAPLUS
- (20) Petersdorf, E; Blood 1998, V92, P3515 HCAPLUS
- (21) Phillips, T; Cytotherapy 2001, V3, P233
- (22) Przepiorka, D; Bone Marrow Transplant 1995, V15, P825 MEDLINE
- (23) Rebello, P; Cytotherapy. In press
- (24) Riechmann, L; Nature 1988, V332, P323 HCAPLUS
- (25) Roux, E; Blood 1996, V87, P3984 HCAPLUS
- (26) Serrano, J; Blood 2000, V95, P2659 HCAPLUS
- (27) Shlomchik, W; Science 1999, V285, P412 HCAPLUS
- (28) Singhal, S; Bone Marrow Transplant 1996, V18, P1049 MEDLINE
- (29) Slavin, S; Blood 1998, V91, P756 MEDLINE
- (30) Small, T; Blood 1999, V93, P467 HCAPLUS
- (31) Storb, R; Ann N Y Acad Sci 1999, V872, P372 MEDLINE
- (32) Storek, J; Bone Marrow Transplant 1995, V16, P413 MEDLINE
- (33) Szydlo, R; J Clin Oncol 1997, V15, P1767 MEDLINE
- (34) Weinberg, K; Blood 2001, V97, P1458 HCAPLUS
- (35) Williamson, E; Br J Haematol 1999, V104, P560 MEDLINE


IT 21679-14-1, Fludarabine

RL: ADV (Adverse effect, including toxicity); PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(CAMPATH-1H nonmyeloablative conditioning regimen for stem cell transplantation in patients with hematol. malignancy)

RN 21679-14-1 HCAPLUS

CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2002 ACS  
 AN 2002:67591 HCAPLUS  
 DN 136:256859  
 TI Nonmyeloablative conditioning followed by transplantation of genetically modified HLA-matched peripheral blood progenitor cells for hematologic malignancies in patients with **acquired immunodeficiency syndrome**  
 AU Kang, Elizabeth M.; De Witte, Moniek; Malech, Harry; Morgan, Richard A.; Phang, Sheila; Carter, Charles; Leitman, Susan F.; Childs, Richard; Barrett, A. John; Little, Richard; Tisdale, John F.  
 CS Molecular and Clinical Hematology Branch, National Institute of Diabetes and Digestive and Kidney Diseases, National Institutes of Health, Bethesda, MD, 20892, USA  
 SO Blood (2002), 99(2), 698-701  
 CODEN: BLOOAW; ISSN: 0006-4971  
 PB American Society of Hematology  
 DT Journal  
 LA English  
 CC 1-6 (Pharmacology)  
 Section cross-reference(s): 15  
 AB To assess the safety and efficacy of nonmyeloablative **allogeneic** transplantation in patients with **HIV** infection, a clin. protocol was initiated in patients with refractory hematol. malignancies and concomitant **HIV** infection. The results from the first 2 patients are reported. The indications for transplantation were treatment-related acute myelogenous leukemia and primary refractory Hodgkin disease in patients 1 and 2, resp. Only patient 1 received genetically modified cells. Both patients tolerated the procedure well with minimal toxicity, and complete remissions were achieved in both patients, but patient 2 died of relapsed Hodgkin disease 12 mo after transplantation. Patient 1 continues in complete remission with undetectable **HIV** levels and rising CD4 counts, and with both the therapeutic and control gene transfer vectors remaining detectable at low levels more than 2 yr after transplantation. These results suggest that nonmyeloablative **allogeneic** transplantation in the context of highly active antiretroviral therapy is feasible in patients with treatment-sensitive **HIV** infection.  
 ST **HIV AIDS** leukemia Hodgkin's CMV toxoplasmosis therapy;  
**hematopoietic** stem cell transplant **HIV** antiviral immunosuppressant antitumor  
 IT Histocompatibility antigens  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (HLA; hematol. malignancies in patients with **AIDS**:  
 nonmyeloablative conditioning followed by transplantation of  
 genetically modified HLA-matched peripheral blood progenitor cells)  
 IT Antitumor agents  
 (Hodgkin's disease inhibitors; hematol. malignancies in patients with **AIDS**: nonmyeloablative conditioning followed by transplantation  
 of genetically modified HLA-matched peripheral blood progenitor cells)  
 IT Antitumor agents  
 (acute myelogenous leukemia; hematol. malignancies in patients with **AIDS**: nonmyeloablative conditioning followed by transplantation  
 of genetically modified HLA-matched peripheral blood progenitor cells)  
 IT Leukemia  
 (acute myelogenous; hematol. malignancies in patients with **AIDS**  
 : nonmyeloablative conditioning followed by transplantation of  
 genetically modified HLA-matched peripheral blood progenitor cells)  
 IT **Transplant and Transplantation**  
 (**allotransplant**, bone marrow; hematol. malignancies in  
 patients with **AIDS**: nonmyeloablative conditioning followed by  
 transplantation of genetically modified HLA-matched peripheral blood  
 progenitor cells)

- IT Bone marrow  
(**allotransplant**; hematol. malignancies in patients with  
**AIDS**: nonmyeloablative conditioning followed by transplantation  
of genetically modified HLA-matched peripheral blood progenitor cells)
- IT **Transplant and Transplantation**  
(**graft-vs.-host** reaction; hematol. malignancies in  
patients with **AIDS**: nonmyeloablative conditioning followed by  
transplantation of genetically modified HLA-matched peripheral blood  
progenitor cells)
- IT **AIDS** (disease)  
Anti-**AIDS** agents  
Antibiotics  
Antiviral agents  
CD4-positive T cell  
**Cytomegalovirus**  
Hodgkin's disease  
Human  
**Immunosuppressants**  
(hematol. malignancies in patients with **AIDS**:  
nonmyeloablative conditioning followed by transplantation of  
genetically modified HLA-matched peripheral blood progenitor cells)
- IT Interferons  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(hematol. malignancies in patients with **AIDS**:  
nonmyeloablative conditioning followed by transplantation of  
genetically modified HLA-matched peripheral blood progenitor cells)
- IT Hodgkin's disease  
(inhibitors; hematol. malignancies in patients with **AIDS**:  
nonmyeloablative conditioning followed by transplantation of  
genetically modified HLA-matched peripheral blood progenitor cells)
- IT **Hematopoietic precursor cell**  
(stem; hematol. malignancies in patients with **AIDS**:  
nonmyeloablative conditioning followed by transplantation of  
genetically modified HLA-matched peripheral blood progenitor cells)
- IT Toxoplasma gondii  
(toxoplasmosis from; hematol. malignancies in patients with  
**acquired immunodeficiency syndrome**:  
nonmyeloablative conditioning followed by transplantation of  
genetically modified HLA-matched peripheral blood progenitor cells)
- IT 50-18-0, Cyclophosphamide 53-03-2, Prednisone 3056-17-5, Stavudine  
8064-90-2, Bactrim **21679-14-1, Fludarabine**  
59277-89-3, Acyclovir 70458-96-7, Norfloxacin 79217-60-0, Cyclosporin  
82410-32-0, Ganciclovir 134678-17-4, Lamivudine 136470-78-5, Abacavir  
150378-17-9, Indinavir 159989-64-7, Nelfinavir  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)  
(hematol. malignancies in patients with **AIDS**:  
nonmyeloablative conditioning followed by transplantation of  
genetically modified HLA-matched peripheral blood progenitor cells)
- RE.CNT 29 THERE ARE 29 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Anderlini, P; Bone Marrow Transplant 2000, V26, P615 MEDLINE
- (2) Angelucci, E; Haematologica 1990, V75, P285 MEDLINE
- (3) Armitage, J; N Engl J Med 1994, V330, P827 MEDLINE
- (4) Bar, B; J Clin Oncol 1993, V11, P513 MEDLINE
- (5) Barrett, A; Bone Marrow Transplant 1998, V21, P543 MEDLINE
- (6) Carella, A; J Clin Oncol 2000, V18, P3918 MEDLINE
- (7) Childs, R; Blood 1999, V94, P3234 HCAPLUS
- (8) Childs, R; N Engl J Med 2000, V343, P750 MEDLINE
- (9) Cooper, M; J Acquir Immune Defic Syndr 1993, V6, P277 MEDLINE
- (10) Dann, E; Bone Marrow Transplant 1997, V20, P369 MEDLINE
- (11) Drobyski, W; Blood 1993, V82, P2310 MEDLINE

- (12) Dunbar, C; Blood 1995, V85, P3048 HCAPLUS
- (13) Giralt, S; Blood 1997, V89, P4531 HCAPLUS
- (14) Giri, N; J Paediatr Child Health 1992, V28, P331 MEDLINE
- (15) Goerner, M; Blood 1999, V94, P2287 HCAPLUS
- (16) Graber, C; Bone Marrow Transplant 2001, V27, P775 MEDLINE
- (17) Kahn, J; N Engl J Med 1998, V339, P33 HCAPLUS
- (18) Kang, E; Mol Ther 2001, V3, P911 HCAPLUS
- (19) Kiem, H; Blood 1998, V92, P1878 HCAPLUS
- (20) Kolb, H; Blood 1990, V76, P2462 MEDLINE
- (21) Malech, H; Blood 1998, V92, P690a
- (22) Malech, H; Stem Cells 2000, V18, P155 MEDLINE
- (23) Mautino, M; J Virol 2001, V75, P3590 HCAPLUS
- (24) Morgan, R; Hum Gene Ther 1996, V7, P1281 MEDLINE
- (25) Peters, S; Exp Hematol 1995, V23, P461 HCAPLUS
- (26) Porter, D; N Engl J Med 1994, V330, P100 MEDLINE
- (27) Qin, S; Br J Haematol 1999, V107, P162 MEDLINE
- (28) Slavin, S; Blood 1998, V91, P756 MEDLINE
- (29) Tisdale, J; Blood 1998, V92, P1131 HCAPLUS

IT 21679-14-1, **Fludarabine**


RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(hematol. malignancies in patients with **AIDS**:  
nonmyeloablative conditioning followed by transplantation of  
genetically modified HLA-matched peripheral blood progenitor cells)

RN 21679-14-1 HCAPLUS

CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:880342 HCAPLUS

DN 136:161053

TI Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with **fludarabine**, low-dose total body irradiation, and posttransplantation cyclophosphamide

AU Luznik, Leo; Jalla, Sanju; Engstrom, Laura W.; Iannone, Robert; Fuchs, Ephraim J.

CS Divisions of Hematopoiesis/Immunology, Hematologic Malignancies, Johns Hopkins Oncology Center, Baltimore, MD, USA

SO Blood (2001), 98(12), 3456-3464

CODEN: BLOOAW; ISSN: 0006-4971

PB American Society of Hematology

DT Journal

LA English

CC 1-7 (Pharmacology)

Section cross-reference(s): 15

AB Treatment of leukemia by myeloablative conditioning and transplantation of major histocompatibility complex (MHC)-mismatched stem cells is generally

avoided because of the high risk of **graft rejection** or lethal **graft-vs.-host disease (GVHD)**. This study shows that MHC-incompatible cells can engraft stably after nonmyeloablative conditioning with immunosuppressive chemotherapy and low-dose total body irradiation (TBI). Long-term mixed **hematopoietic** chimerism, clonal deletion of donor-reactive **T cells**, and bidirectional cytotoxic **T-cell** tolerance were achieved by transplanting MHC-mismatched marrow cells into recipients conditioned with pretransplantation **fludarabine** or cyclophosphamide (Cy), 50 to 200 cGy TBI on day -1, and Cy 200 mg/kg i.p. on day 3. In this model, long-term donor chimerism was proportional to the dose of TBI or donor marrow cells. Pretransplantation **fludarabine** and posttransplantation Cy were both required for alloengraftment, but the drugs had additional effects. For example, **fludarabine** sensitized **host** stem cells to the toxicity of TBI, because animals conditioned with both agents had higher chimerism than animals conditioned with TBI alone ( $P < .05$ ). Also, post-transplantation Cy attenuated lethal and nonlethal GVH reactions, because F1 recipients of **host**-reactive, parental spleen cells survived longer ( $P < .05$ ) and had lower donor cell chimerism ( $P < .01$ ) if they received posttransplantation Cy than if they did not. Finally, delayed infusions of donor **lymphocytes** into mixed chimeras prolonged survival after leukemia challenge ( $P < .0001$ ) without causing lethal **GVHD**. These results indicate that stable engraftment of MHC-incompatible cells can be induced after **fludarabine**-based, nonmyeloablative conditioning and that it serves as a platform for adoptive immunotherapy with donor **lymphocyte** infusions.

- ST leukemia myeloablation stem cell transplant immunosuppressant radiation  
IT Histocompatibility antigens  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(MHC (major histocompatibility complex); durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with **fludarabine**, low-dose total body irradiation., and posttransplantation cyclophosphamide)  
IT Adoptive immunotherapy  
Immunosuppressants  
Ionizing radiation  
Leukemia  
Transplant and Transplantation  
Transplant rejection  
(durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with **fludarabine**, low-dose total body irradiation., and posttransplantation cyclophosphamide)  
IT Transplant and Transplantation  
(**graft-vs.-host** reaction; durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with **fludarabine**, low-dose total body irradiation., and posttransplantation cyclophosphamide)  
IT Hematopoietic precursor cell  
(stem; durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with **fludarabine**, low-dose total body irradiation., and posttransplantation cyclophosphamide)  
IT 50-18-0, Cyclophosphamide 21679-14-1, **Fludarabine**  
RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with **fludarabine**, low-dose total body irradiation., and posttransplantation cyclophosphamide)  
RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD

- RE  
(1) Abe, R; J Immunol 1991, V147, P739 HCAPLUS  
(2) Anasetti, C; N Engl J Med 1989, V320, P197 MEDLINE

- (3) Antin, J; Blood 1992, V80, P2964 MEDLINE
- (4) Ash, R; Bone Marrow Transplant 1991, V7, P443 MEDLINE
- (5) Aversa, F; J Clin Oncol 1999, V17, P1545 MEDLINE
- (6) Blazar, B; J Immunol 1997, V159, P3460 HCAPLUS
- (7) Bunn, D; Clin Nephrol 1996, V45, P29 HCAPLUS
- (8) Cheson, B; J Clin Oncol 1995, V13, P2431 HCAPLUS
- (9) Childs, R; Blood 1999, V94, P3234 HCAPLUS
- (10) Chun, H; J Clin Oncol 1991, V9, P175 MEDLINE
- (11) Clift, R; Blood 1990, V76, P1867 MEDLINE
- (12) Collins, R; J Clin Oncol 1997, V15, P433
- (13) Colson, Y; J Immunol 1995, V155, P4179 HCAPLUS
- (14) Colson, Y; J Immunol 1996, V157, P2820 HCAPLUS
- (15) Curtis, R; Blood 1999, V94, P2208 HCAPLUS
- (16) de Vries-van der Zwan, A; Blood 1997, V89, P2596 HCAPLUS
- (17) de Vries-van der Zwan, A; Transpl Immunol 1998, V6, P147 MEDLINE
- (18) Enright, H; Transplantation 1993, V55, P1339 MEDLINE
- (19) Eto, M; J Exp Med 1990, V171, P97 HCAPLUS
- (20) Frank, D; Nat Med 1999, V5, P444 HCAPLUS
- (21) Fuchs, E; Science 1992, V258, P1156 MEDLINE
- (22) Giralt, S; Blood 1997, V89, P4531 HCAPLUS
- (23) Gregoire, V; Cancer Res 1994, V54, P468 HCAPLUS
- (24) Gregoire, V; Int J Radiat Oncol Biol Phys 1994, V30, P363 HCAPLUS
- (25) Guinan, E; N Engl J Med 1999, V340, P1704 HCAPLUS
- (26) Henslee-Downey, P; Blood 1997, V89, P3864 HCAPLUS
- (27) Ildstad, S; J Exp Med 1985, V162, P231 MEDLINE
- (28) Ildstad, S; J Immunol 1986, V136, P28 MEDLINE
- (29) Johnson, B; Blood 1995, V85, P3302 HCAPLUS
- (30) Johnson, B; Bone Marrow Transpl 1993, V11, P329 MEDLINE
- (31) Johnson, B; Bone Marrow Transplant 1993, V11, P329 MEDLINE
- (32) Johnson, B; J Immunol 1999, V163, P6479 HCAPLUS
- (33) Khouri, I; J Clin Oncol 1998, V16, P2817 MEDLINE
- (34) Kolb, H; Blood 1995, V86, P2041 HCAPLUS
- (35) Leong, L; Eur J Immunol 1992, V22, P2825 MEDLINE
- (36) Matsuzaki, G; J Immunol 1990, V145, P46 MEDLINE
- (37) Mayumi, H; J Exp Med 1989, V169, P213 MEDLINE
- (38) Mayumi, H; Transplantation 1986, V42, P417 HCAPLUS
- (39) Pelot, M; Biol Blood Marrow Transplant 1999, V5, P133 MEDLINE
- (40) Petersdorf, E; Curr Opin Immunol 1999, V11, P521 HCAPLUS
- (41) Petrus, M; Biol Blood Marrow Transplant 2000, V6, P182 HCAPLUS
- (42) Plunkett, W; Pharmacol Ther 1991, V49, P239 HCAPLUS
- (43) Ramsdell, F; Science 1989, V246, P1038 HCAPLUS
- (44) Ryan, J; Immunogenetics 1991, V34, P88 HCAPLUS
- (45) Slavin, S; Blood 1998, V91, P756 MEDLINE
- (46) Spitzer, T; Biol Blood Marrow Transplant 2000, V6, P309 MEDLINE
- (47) Sullivan, K; N Engl J Med 1989, V320, P828 MEDLINE
- (48) Sykes, M; J Exp Med 1988, V168, P2391 MEDLINE
- (49) Sykes, M; Lancet 1999, V353, P1755 MEDLINE
- (50) Sykes, M; Nat Med 1997, V3, P783 HCAPLUS
- (51) Thomas, E; Hematopoietic cell transplantation 1999
- (52) Tollemar, J; Bone Marrow Transplant 1989, V4, P635 MEDLINE
- (53) Tomita, Y; J Immunol 1994, V153, P1087 HCAPLUS
- (54) Tornita, Y; J Immunol 2000, V165, P34
- (55) Truitt, R; Blood 1991, V77, P2515 MEDLINE
- (56) Tutschka, P; Transplantation 1981, V32, P203 MEDLINE
- (57) Uharek, L; Blood 1992, V79, P1612 MEDLINE
- (58) Via, C; J Immunol 1987, V139, P1840 MEDLINE
- (59) Wekerle, T; J Exp Med 1998, V187, P2037 HCAPLUS


IT **21679-14-1, Fludarabine**

RL: PAC (Pharmacological activity); THU (Therapeutic use); BIOL  
(Biological study); USES (Uses)

(durable engraftment of major histocompatibility complex-incompatible  
cells after nonmyeloablative conditioning with **fludarabine**,  
low-dose total body irradiation, and posttransplantation cyclophosphamide)

RN 21679-14-1 HCAPLUS  
CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2002 ACS  
AN 2001:880308 HCAPLUS  
DN 136:165781  
TI The effect of pretransplant interferon therapy on the outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase  
AU Lee, Stephanie J.; Klein, John P.; Anasetti, Claudio; Antin, Joseph H.; Loberiza, Fausto R.; Bolwell, Brian J.; LeMaistre, Charles F.; Litzow, Mark R.; Marks, David; **Waller, Edmund K.**; Matlack, Marie; Giralt, Sergio; Horowitz, Mary M.  
CS Chronic Leukemia Working Committee of the International Bone Marrow Transplant Registry, Health Policy Institute, Medical College of Wisconsin, Milwaukee, WI, 53226, USA  
SO Blood (2001), 98(12), 3205-3211  
CODEN: BLOOAW; ISSN: 0006-4971  
PB American Society of Hematology  
DT Journal  
LA English  
CC 15-5 (Immunochemistry)  
AB Various therapeutic options are available for patients with chronic myelogenous leukemia. Allogeneic stem cell transplantation, though often curative, is assocd. with high nonrelapse mortality and long-term morbidity, particularly when cells from unrelated donors are used. Many physicians and patients opt for a trial of interferon-.alpha. (IFN)-based therapy first, reserving transplantation for patients with inadequate response or intolerance to IFN. Data were analyzed on 740 patients receiving unrelated donor transplants for chronic myelogenous leukemia in first chronic phase provided by the International Bone Marrow Transplant Registry and the National Marrow Donor Program to see whether IFN pretreatment compromised transplantation outcome. A total of 489 (66%) had received IFN prior to transplantation; 251 (34%) had not. Disease characteristics in the 2 groups were similar at diagnosis but at the time of transplantation, hematol. parameters and wt. were lower in IFN patients and the interval between diagnosis and transplantation was longer. After adjustment for baseline covariates, no effect of IFN exposure was found on overall survival, leukemia-free survival, nonrelapse mortality, engraftment, relapse, or acute or chronic graft-vs.-host disease. Evaluation of effects based on duration of therapy and time off IFN prior to transplantation was limited by missing data and confounding with IFN intolerance and disease responsiveness. In conclusion, no evidence was found for an independent adverse effect of IFN pretreatment on the outcome of subsequent unrelated donor transplantation.  
ST interferon allogeneic stem cell transplant myelogenous leukemia

- IT **Transplant and Transplantation**  
(allotransplant; effect of pretransplant interferon therapy on outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase)
- IT Antitumor agents  
(chronic myelocytic leukemia; effect of pretransplant interferon therapy on outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase)
- IT Human  
(effect of pretransplant interferon therapy on outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase)
- IT Interferons  
RL: ADV (Adverse effect, including toxicity); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(effect of pretransplant interferon therapy on outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase)
- IT **Transplant and Transplantation**  
(graft-vs.-host reaction; effect of pretransplant interferon therapy on outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase)
- IT **Hematopoietic precursor cell**  
(stem; effect of pretransplant interferon therapy on outcome of unrelated donor hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in first chronic phase)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
RE

- (1) Allan, N; Lancet 1995, V345, P1392 MEDLINE
- (2) Anon; J Natl Cancer Inst 1997, V89, P1616
- (3) Anon; N Engl J Med 1994, V330, P820
- (4) Baron, S; JAMA 1991, V266, P1375 HCAPLUS
- (5) Beelen, D; Blood 1995, V85, P2981 HCAPLUS
- (6) Beelen, D; Blood 1999, V93, P1779 HCAPLUS
- (7) Druker, B; N Engl J Med 2001, V344, P1031 HCAPLUS
- (8) Druker, B; N Engl J Med 2001, V344, P1038 HCAPLUS
- (9) Giralt, S; Blood 2000, V95, P410 HCAPLUS
- (10) Giralt, S; J Clin Oncol 1993, V11, P1055 MEDLINE
- (11) Gratwohl, A; Lancet 1998, V352, P1087 MEDLINE
- (12) Guilhot, F; N Engl J Med 1997, V337, P223 HCAPLUS
- (13) Hansen, J; N Engl J Med 1998, V338, P962 MEDLINE
- (14) Hasford, J; J Natl Cancer Inst 1998, V90, P850 MEDLINE
- (15) Hehlmann, R; Blood 1994, V84, P4064 HCAPLUS
- (16) Hehlmann, R; Blood 1999, V94, P3668 HCAPLUS
- (17) Holler, E; Ann Hematol 1995, V1996, PA96
- (18) Kantarjian, H; Ann Intern Med 1995, V122, P254 MEDLINE
- (19) McGlave, P; Blood 2000, V95, P2219 HCAPLUS
- (20) Morton, A; Blood 1998, V92, P394 HCAPLUS
- (21) Ohnishi, K; Blood 1995, V86, P906 HCAPLUS
- (22) Ohnishi, K; Leuk Res 1998, V22, P779 HCAPLUS
- (23) Pigneux, A; Blood 1998, V92, P495a
- (24) Shepherd, P; Blood 1995, V86, P94a
- (25) Sokal, J; Blood 1984, V63, P789 MEDLINE
- (26) Sokal, J; Blood 1985, V66, P1352 MEDLINE
- (27) Talpaz, M; Ann Intern Med 1991, V114, P532 MEDLINE
- (28) The Benelux CML Study Group; Blood 1998, V91, P2713 HCAPLUS
- (29) The Italian Cooperative Study Group on Chronic Myeloid Leukemia; Blood 1998, V92, P1541 HCAPLUS
- (30) Tomas, J; Bone Marrow Transplant 1998, V22, P47 MEDLINE
- (31) Tura, S; Blood 1998, V92, P317a
- (32) Zuffa, E; Haematologica 1998, V83, P231 HCAPLUS

L77 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2002 ACS  
 AN 2001:647544 HCAPLUS  
 DN 135:352467  
 TI Dose-reduced conditioning and **allogeneic hematopoietic**  
 stem cell transplantation from unrelated donors in 42 patients  
 AU Bornhauser, Martin; Thiede, Christian; Platzbecker, Uwe; Jenke, Andreas;  
 Helwig, Anett; Plettig, Runa; Freiberg-Richter, Jens; Rolbig, Christoph;  
 Geissler, Gabriele; Lutterbeck, Karin; Oelschlagel, Uta; Ehninger, Gerhard  
 CS Medizinische Klinik und Poliklinik I, Universitätsklinikum Carl Gustav  
 Carus, Dresden, 01307, Germany  
 SO Clinical Cancer Research (2001), 7(8), 2254-2262  
 CODEN: CCREF4; ISSN: 1078-0432  
 PB American Association for Cancer Research  
 DT Journal  
 LA English  
 CC 1-6 (Pharmacology)  
 Section cross-reference(s): 15  
 AB A **fludarabine**-based "nonmyeloablative" preparative regimen was  
 investigated in 42 patients with hematol. malignancies receiving  
**hematopoietic stem cell grafts** from unrelated  
 volunteer donors. Recipient conditioning consisted of **fludarabine**  
 30 mg/m<sup>2</sup> on days -6 to -2 and i.v. busulfan 3.3 mg/kg on days -6 to -5.  
 Antithymocyte globulin was added at 2.5 mg/kg i.v. on days -5 to -2. The  
 patients were grafted with bone marrow (n = 13) or peripheral blood stem  
**cells** either unmanipulated (n = 20) or CD34+ selected (n = 9).  
**Graft-vs.-host disease** prophylaxis was  
 performed with cyclosporine A (CsA, n = 12), CsA/methotrexate (n = 12), or  
 CsA/mycophenolate mofetil (n = 18). With a median follow-up of 13 mo  
 (range, 5-26 mo), the actuarial **disease**-free survival is 64% and  
 38% for patients with lymphoid malignancies and std.-risk leukemia  
 compared with only 14% for patients with high-risk **disease**. The  
 main cause of treatment failure was relapse of **disease** in  
 high-risk patients (n = 14). An increased incidence of primary (n = 1) or  
 secondary **graft**-failure (n = 8) was obsd. (21%). Chimerism  
 anal. of CD56+/CD3--sorted **natural killer** (NK)  
**cells**, available in 10 patients, showed an impaired increase of  
 donor NK **cell** chimerism between day 10 and 30 after  
 transplantation in three of four patients with **graft** failure,  
 whereas the percentage of donor NK **cells** surpassed 75% in all of  
 the six patients with stable engraftment. Unrelated transplants after  
 dose-reduced conditioning are assocd. with a higher risk of **graft**  
 -failure. Pretransplant **host** immunosuppression has to be  
 optimized to overcome resistance to **grafts** from unrelated donors  
 after nonmyeloablative conditioning therapy.  
 ST antileukemic immunosuppressant unrelated **allogeneic** transplant  
 graft disease  
 IT **Transplant and Transplantation**  
 (allotransplant; dose-reduced conditioning and  
**allogeneic hematopoietic** stem cell transplantation  
 from unrelated donors in humans)  
 IT Immunoglobulins  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
 study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
 (Uses)  
 (antithymocyte globulins; dose-reduced conditioning and  
**allogeneic hematopoietic** stem cell transplantation  
 from unrelated donors in humans)  
 IT **Immunosuppressants**  
 (dose-reduced conditioning and **allogeneic**  
**hematopoietic** stem cell transplantation from unrelated donors  
 in humans)  
 IT Chimeric gene  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL

(Biological study); PROC (Process)  
 (dose-reduced conditioning and **allogeneic**  
**hematopoietic** stem cell transplantation from unrelated donors  
 in humans)

IT **Transplant and Transplantation**

(**graft-vs.-host** reaction; dose-reduced conditioning  
 and **allogeneic hematopoietic** stem cell  
 transplantation from unrelated donors in humans)

IT Antitumor agents

(leukemia; dose-reduced conditioning and **allogeneic**  
**hematopoietic** stem cell transplantation from unrelated donors  
 in humans)

IT **Hematopoietic precursor cell**

(stem; dose-reduced conditioning and **allogeneic**  
**hematopoietic** stem cell transplantation from unrelated donors  
 in humans)

IT 55-98-1, Busulfan 59-05-2, Methotrexate **21679-14-1**,  
**Fludarabine** 59865-13-3, Cyclosporine A 128794-94-5,  
 Mycophenolate mofetil

RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or  
 effector, except adverse); BSU (Biological study, unclassified); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)

(dose-reduced conditioning and **allogeneic**  
**hematopoietic** stem cell transplantation from unrelated donors  
 in humans)

RE.CNT 32 THERE ARE 32 CITED REFERENCES AVAILABLE FOR THIS RECORD  
 RE

- (1) Beelen, D; Blood 1995, V85, P2981 HCAPLUS
- (2) Bornhaeuser, M; Bone Marrow Transplant 2000, V26, P119
- (3) Giralt, S; Blood 1998, V92(Suppl 1), P289
- (4) Gyger, M; Exp Hematol 1998, V26, P426 MEDLINE
- (5) Kaplan, E; J Am Stat Assoc 1958, V53, P457
- (6) Khouri, I; J Clin Oncol 1998, V16, P2817 MEDLINE
- (7) Kolb, H; Blood 1995, V86, P2041 HCAPLUS
- (8) Kottaridis, P; Blood 2000, V96, P2419 HCAPLUS
- (9) Lamb, L; Bone Marrow Transplant 1996, V17, P1021
- (10) Lamparelli, T; Bone Marrow Transplant 1997, V20, P1057 MEDLINE
- (11) Lang, P; Bone Marrow Transplant 1999, V24, P583 MEDLINE
- (12) McGlave, P; Blood 2000, V95, P2219 HCAPLUS
- (13) McSweeney, P; Blood 1998, V92(Suppl 1), P519
- (14) Mutis, T; Nat Med 1999, V5, P839 HCAPLUS
- (15) Nagler, A; Exp Hematol 2000, V28, P1096 MEDLINE
- (16) Ottinger, H; Bone Marrow Transplant 1997, V20, P101 MEDLINE
- (17) Petersdorf, E; Blood 1998, V92, P3515 HCAPLUS
- (18) Przepiorka, D; Bone Marrow Transplant 1995, V15, P825 MEDLINE
- (19) Raff, R; Blood 1986, V68, P861 MEDLINE
- (20) Sandmaier, B; Blood 1999, V94(Suppl 1), P318
- (21) Schuler, U; Blood 1997, V90(Suppl 1), P365
- (22) Sierra, J; Blood 1997, V89, P4226 HCAPLUS
- (23) Slavin, S; Blood 1996, V87, P2195 HCAPLUS
- (24) Slavin, S; Blood 1998, V91, P756 MEDLINE
- (25) Spitzer, T; Biol Blood Marrow Transplant 2000, V6, P309 MEDLINE
- (26) Stewart, F; Blood 1998, V91, P3681 HCAPLUS
- (27) Storb, R; Blood 1997, V89, P3048 HCAPLUS
- (28) Sullivan, K; Semin Hematol 1991, V28, P250 MEDLINE
- (29) Sykes, M; Lancet 1999, V353, P1755 MEDLINE
- (30) Thiede, C; Bone Marrow Transplant 1999, V23, P1055 MEDLINE
- (31) Wheeler, K; Blood 2000, V96, P2412 HCAPLUS
- (32) Yu, C; Blood 1998, V91, P2581 HCAPLUS

IT **21679-14-1, Fludarabine**


RL: ADV (Adverse effect, including toxicity); BAC (Biological activity or  
 effector, except adverse); BSU (Biological study, unclassified); THU  
 (Therapeutic use); BIOL (Biological study); USES (Uses)

(dose-reduced conditioning and **allogeneic**  
**hematopoietic** stem cell transplantation from unrelated donors  
 in humans)

RN 21679-14-1 HCAPLUS

CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX  
 NAME)

Absolute stereochemistry.



L77 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2002 ACS

AN 2001:549793 HCAPLUS

DN 135:327107

TI Nonmyeloablative **hematopoietic** cell transplantation: Replacing  
 high-dose cytotoxic therapy by the graft-versus-tumor effect

AU Feinstein, Lyle; Sandmaier, Brenda; Maloney, David; McSweeney, Peter A.;  
 Maris, Michael; Flowers, Christopher; Radich, Jerry; Little, Marie-Terese;  
 Nash, Richard A.; Chauncey, Thomas; Woolfrey, Ann; Georges, George; Kiem,  
 Hans-Peter; Zaucha, Jan M.; Blume, Karl G.; Shizuru, Judith; Niederwieser,  
 Dietger; Storb, Rainer

CS Fred Hutchinson Cancer Research Center, Seattle, WA, 98109-1024, USA

SO Annals of the New York Academy of Sciences (2001), 938 (Hematopoietic Stem  
 Cells 2000), 328-339

CODEN: ANYAA9; ISSN: 0077-8923

PB New York Academy of Sciences

DT Journal

LA English

CC 1-7 (Pharmacology)

Section cross-reference(s): 8

AB Conventional allografting produces considerable regimen-related toxicities  
 that generally limit this treatment to patients younger than 55 yr and in  
 otherwise good medical condition. **T cell**-mediated  
**graft-vs.-tumor** (GVT) effects are known to play an important role  
 in the elimination of malignant **disease** after  
**allotransplants**. A minimally myelosuppressive regiment that  
 relies on immunosuppression for **allogeneic** engraftment was  
 developed to reduce toxicities while optimizing GVT effects.  
 Pre-transplant total-body irradiation (200 cGy) followed by post-transplant  
 immunosuppression with cyclosporine (CSP) and mycophenolate mofetil (MMF)  
 permitted human leukocyte antigen (HLA)-matched sibling donor  
**hematopoietic** cell engraftment in 82% of patients (n = 55) without  
 prior high-dose therapy. The addition of **fludarabine** (90 mg/M2)  
 facilitated engraftment in all 28 subsequent patients. Overall, fatal  
 progression of underlying **disease** occurred in 20% of patients  
 after transplant. Non-relapse mortality occurred in 11% of patients.  
 Toxicities were low. Grade 2-4 acute **graft-vs.-host**  
**disease** (GVHD) associated with primary engraftment  
 developed in 47% of patients, and was readily controlled in all but two  
 patients. Donor **lymphocyte** infusions (DLI) were not very  
 effective at converting a low degree of mixed donor/host

chimerism to full donor chimerism; however, the addn. of **fludarabine** reduced the need for DLI. With a median follow-up of 244 days, 68% of patients were alive, with 42% of patients in complete remission, including mol. remissions. Remissions occurred gradually over periods of weeks to a year. If long-term efficacy is demonstrated, such a strategy would expand treatment options for patients who would otherwise be excluded from conventional allografting.

- ST nonmyeloablative **hematopoietic** cell transplantation  
immunosuppressant antitumor
- IT Histocompatibility antigens  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(HLA; nonmyeloablative **hematopoietic** cell transplantation  
relying on immunosuppression for treatment of hematol. malignancies in humans)
- IT **Transplant and Transplantation**  
(allotransplant, **hematopoietic** stem cell;  
nonmyeloablative **hematopoietic** cell transplantation relying  
on immunosuppression for treatment of hematol. malignancies in humans)
- IT **Transplant and Transplantation**  
(bone marrow; nonmyeloablative **hematopoietic** cell  
transplantation relying on immunosuppression for treatment of hematol.  
malignancies in humans)
- IT **Transplant and Transplantation**  
(graft-vs.-host reaction; nonmyeloablative  
**hematopoietic** cell transplantation relying on immunosuppression  
for treatment of hematol. malignancies in humans)
- IT Antitumor agents  
(hematol. malignancy; nonmyeloablative **hematopoietic** cell  
transplantation relying on immunosuppression for treatment of hematol.  
malignancies in humans)
- IT Neoplasm  
(hematol.; nonmyeloablative **hematopoietic** cell  
transplantation relying on immunosuppression for treatment of hematol.  
malignancies in humans)
- IT Lymphocyte  
(infusion; nonmyeloablative **hematopoietic** cell  
transplantation relying on immunosuppression for treatment of hematol.  
malignancies in humans)
- IT **Hematopoietic precursor cell**  
**Immunosuppressants**  
Radiotherapy  
(nonmyeloablative **hematopoietic** cell transplantation relying  
on immunosuppression for treatment of hematol. malignancies in humans)
- IT Bone marrow  
(transplant; nonmyeloablative **hematopoietic** cell  
transplantation relying on immunosuppression for treatment of hematol.  
malignancies in humans)
- IT **21679-14-1, Fludarabine** 59865-13-3, Cyclosporine  
128794-94-5, Mycophenolate mofetil  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological  
study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES  
(Uses)  
(nonmyeloablative **hematopoietic** cell transplantation relying  
on immunosuppression for treatment of hematol. malignancies in humans)


RE.CNT 59 THERE ARE 59 CITED REFERENCES AVAILABLE FOR THIS RECORD

RE

- (1) Andreani, M; Blood 1996, V87, P3494 HCAPLUS
- (2) Andreani, M; Bone Marrow Transplant 2000, V25, P401 MEDLINE
- (3) Antin, J; Blood 1992, V80, P2964 MEDLINE
- (4) Bensinger, W; Blood 1999, V94(Suppl 1), P368a
- (5) Bhatia, S; Blood 1996, V87, P3633 HCAPLUS
- (6) Butturini, A; Bone Marrow Transplant 1987, V2, P233 MEDLINE

- (8) Champlin, R; Blood 2000, V95, P3702 HCAPLUS
  - (9) Childs, R; Blood 1999, V94, P3234 HCAPLUS
  - (10) Collins, R; J Clin Oncol 1997, V15, P433
  - (11) Drobyski, W; Blood 1993, V82, P2310 MEDLINE
  - (12) Fefer, A; Cellular Immunotherapy of Cancer 1987, P401 MEDLINE
  - (13) Flowers, C; Blood 2242
  - (14) Flowers, C; Blood 2000, V96(Suppl 1), P521a
  - (15) Fuchimoto, Y; J Clin Invest 2000, V105, P1779 HCAPLUS
  - (16) Giralt, S; Blood 1997, V89, P4531 HCAPLUS
  - (17) Gorin, N; Bone Marrow Transplant 1996, V18, P111 MEDLINE
  - (18) Heldal, D; Bone Marrow Transplant 2000, V25, P1129 MEDLINE
  - (19) Horowitz, M; Blood 1990, V75, P555 MEDLINE
  - (20) Khouri, I; J Clin Oncol 1998, V16, P2817 MEDLINE
  - (21) Kolb, H; Blood 1995, V86, P2041 HCAPLUS
  - (22) Mackinnon, S; Blood 1995, V86, P1261 HCAPLUS
  - (23) Manilay, J; Transplantation 1998, V66, P96 MEDLINE
  - (24) Maris, M; Blood 2239
  - (25) Maris, M; Blood 2053
  - (26) Maris, M; Blood 2000, V96(Suppl 1), P477a
  - (27) Maris, M; Blood 2000, V96(Suppl 1), P520a
  - (28) McSweeney, P; Blood 1742
  - (29) McSweeney, P; Blood 1999, V94(Suppl 1), P393a
  - (30) Molina, A; Handbook of Bone Marrow Transplantation 2000, P111
  - (31) Nagler, A; Bone Marrow Transplant 2000, V25, P1021 MEDLINE
  - (32) Porter, D; N Engl J Med 1994, V330, P100 MEDLINE
  - (33) Powles, R; Lancet 2000, V355, P1231 MEDLINE
  - (34) Ringden, O; Transplant Proc 1989, V21, P2989 MEDLINE
  - (35) Saito, K; J Immunol 1998, V160, P4225 HCAPLUS
  - (36) Sandmaier, B; Blood 2062
  - (37) Sandmaier, B; Blood 2000, V96(Suppl 1), P479a
  - (38) Shlomchik, W; Science 1999, V285, P412 HCAPLUS
  - (39) Slavin, S; Blood 1998, V91, P756 MEDLINE
  - (40) Spitzer, T; Biol Blood & Marrow Transplant 2000, V6, P309 MEDLINE
  - (41) Storb, R; Blood 1997, V89, P3048 HCAPLUS
  - (42) Storb, R; Blood 1999, V94, P1131 HCAPLUS
  - (43) Storb, R; Blood 1999, V94, P2523 HCAPLUS
  - (44) Sullivan, K; Blood 1989, V73, P1720 MEDLINE
  - (45) Sullivan, K; Cellular Immunotherapy of Cancer 1987, P391 MEDLINE
  - (46) Thomas, E; N Engl J Med P895
  - (47) Thomas, E; N Engl J Med 1975, V292, P832 MEDLINE
  - (48) Tomita, Y; J Immunol 1994, V153, P1087 HCAPLUS
  - (49) van Rhee, F; Blood 1994, V83, P3377 MEDLINE
  - (50) Vermynen, C; Bone Marrow Transplant 1998, V22, P1 MEDLINE
  - (51) Walters, M; Biol Blood & Marrow Transplant 1997, V3, P310 MEDLINE
  - (52) Walters, M; Blood 2000, V95, P1918 HCAPLUS
  - (53) Weiden, P; N Engl J Med 1979, V300, P1068 MEDLINE
  - (54) Weiden, P; N Engl J Med 1981, V304, P1529 MEDLINE
  - (55) Wekerle, T; J Exp Med 1998, V187, P2037 HCAPLUS
  - (56) Yu, X; J Immunol 2000, V164, P4564 HCAPLUS
  - (57) Zaucha, J; Blood 1425
  - (58) Zaucha, J; Blood 1999, V94(Suppl 1), P319a
  - (59) Zittoun, R; N Engl J Med 1995, V332, P217 MEDLINE
- IT 21679-14-1, **Fludarabine**  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (nonmyeloablative **hematopoietic** cell transplantation relying on immunosuppression for treatment of hematol. malignancies in humans)
- RN 21679-14-1 HCAPLUS  
 CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2002 ACS  
 AN 2000:475773 HCAPLUS  
 DN 133:84267  
 TI Non-myeloablative tolerogenic treatment  
 IN Slavin, Shimon; Prigozhina, Tatyana  
 PA Hadasit Medical Research Services and Development Ltd., Israel; Baxter International Inc.  
 SO PCT Int. Appl., 119 pp.  
 CODEN: PIXXD2  
 DT Patent  
 LA English  
 IC ICM C12N005-08  
 ICS A61K035-12; A61K035-28; A61K039-00; A61P037-02  
 CC 1-7 (Pharmacology)  
 Section cross-reference(s): 15

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000040701	A2	20000713	WO 1999-US30704	19991223
	WO 2000040701	A3	20001221		
	W: CA, IL, JP, MX				
	RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
	EP 1141246	A2	20011010	EP 1999-968946	19991223
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
PRAI	US 1998-222011	A	19981231		
	WO 1999-US30704	W	19991223		
AB	The present invention features a method of inducing donor-specific tolerance in a host. Tolerogenic treatments of the present invention may be administered to a host prior to transplantation of donor-derived materials. The tolerogenic treatment involves (1) administering an immunosuppressive agent to a host mammal in a non-myeloablative regimen sufficient to decrease, but not necessarily to eliminate, the host mammal's functional <b>T lymphocyte</b> population; (2) infusing donor antigens from a non-syngeneic donor into the host mammal; (3) eliminating those host <b>T lymphocytes</b> responding to the infused donor antigens using a non-myeloablative dose of <b>lymphocytotoxic</b> or tolerizing agent; and (4) administering donor <b>hematopoietic</b> cells to the host mammal. Donor lymphoid cells used for cell therapy of a host mammal can be depleted of host specific immunol. reactivity by methods essentially similar to those used for tolerizing a host mammal prior to transplantation.				
ST	immune tolerance induction donor antigen immunosuppressant; <b>T lymphocyte</b> elimination immunosuppressant immune tolerance;				
IT	<b>Transplant and Transplantation</b> Transplant and Transplantation				

- (bone marrow, induction of immune tolerance to recipient in, **graft-vs.-host disease** prevention in relation to; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT Antigens  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (donor; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT **Transplant and Transplantation**  
 (**graft-vs.-host** reaction, prevention of by immune tolerance induction; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT **T cell (lymphocyte)**  
 (immune tolerance induction in; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT Leukemia  
 Neoplasm  
 (immunotherapy of, immune tolerance induction to prevent **graft-vs.-host disease** in; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT **Immune tolerance**  
**Immunosuppressants**  
**Transplant and Transplantation**  
**Transplant rejection**  
 (non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT Immunotherapy  
 (of leukemia, immune tolerance induction to prevent **graft-vs.-host disease** in; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT Cytokines  
 Interleukin 10  
 Interleukin 2  
 Tumor necrosis factors  
 RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study); PROC (Process)  
 (prodn. in immunotherapy of leukemia, **graft-vs.-host disease** prevention in relation to; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT **Hematopoietic precursor cell**  
 (stem, in immune tolerance induction; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT Antibodies  
 RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (to **T lymphocytes**, in immune tolerance induction; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)
- IT Bone marrow  
 Bone marrow  
 (transplant, induction of immune tolerance to recipient in, **graft-vs.-host disease** prevention in relation to; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)

IT Radiotherapy  
(x-ray, T lymphocyte depletion with, in immune tolerance induction; non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)


IT 50-18-0, Cyclophosphamide 21679-14-1, Fludarabine 88859-04-5  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)

IT 21679-14-1, Fludarabine  
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(non-myeloablative induction of tolerance using donor antigens and immunosuppressants to prevent transplantation rejection)

RN 21679-14-1 HCAPLUS

CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L77 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2002 ACS

AN 2000:335523 HCAPLUS

DN 132:303515

TI Method and compositions for improving allogeneic hematopoietic cell transplantation

IN Waller, Edmund K.

PA Emory University, USA

SO PCT Int. Appl., 22 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM C12N005-00

CC 1-12 (Pharmacology)

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2000027998	A2	20000518	WO 1999-US26773	19991110
	WO 2000027998	A3	20000727		
W:	AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW:	GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,				

DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,  
 CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 EP 1123384 A2 20010816 EP 1999-961649 19991110  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI

PRAI US 1998-189577 A 19981111  
 WO 1999-US26773 W 19991110

AB The invention relates to methods of reducing or preventing graft vs. host disease in an allogeneic hematopoietic system reconstituting cells transplant recipient comprising administering to the recipient allogeneic hematopoietic system reconstituting cells in which the no. of dendritic cells has been effectively reduced, thereby reducing or preventing graft vs. host disease, are provided. Also provided are methods of increasing the chance of survival for an allogeneic hematopoietic system reconstituting cells transplant recipient comprising administering to the recipient allogeneic hematopoietic system reconstituting cells in which the no. of dendritic cells has been effectively reduced, thereby improving the chance for survival of the recipient. Columns for prepg. hematopoietic system reconstituting cells prior to their transplantation are disclosed that provide for the selection of CD34+ cells and the removal of dendritic cell progenitors.

ST graft host disease allogeneic hematopoietic cell; interleukin 3 graft host disease

IT CD antigens

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(CD34 or CD36 or CD45RA; method and compns. for improving allogeneic hematopoietic cell transplantation)

IT **Hematopoietic precursor cell**

(allogeneic; method and compns. for improving allogeneic hematopoietic cell transplantation)

IT **Transplant and Transplantation**

(graft-vs.-host reaction; method and compns. for improving allogeneic hematopoietic cell transplantation)

IT **Transplant and Transplantation**

(method and compns. for improving allogeneic hematopoietic cell transplantation)

IT Antibodies

CD4 (antigen)

Interleukin 3

Interleukin 3 receptors

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(method and compns. for improving allogeneic hematopoietic cell transplantation)

L77 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2002 ACS

AN 1999:344857 HCAPLUS

DN 131:4246

TI Treatment of hematologic disorders

IN Sykes, Megan; Spitzer, Thomas R.

PA The General Hospital Corporation, USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

IC ICM A61K035-14

ICS A61K035-28; A61K035-28; A61K039-395; A61K031-675

CC 15-10 (Immunochemistry)

FAN.CNT 1

PATENT NO.

KIND DATE

APPLICATION NO. DATE


-----  
 PI WO 9925367 A2 19990527 WO 1998-US24209 19981113  
 WO 9925367 A3 19990805  
 W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE,  
 DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG,  
 KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX,  
 NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,  
 UA, UG, US, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM  
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,  
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,  
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG  
 CA 2309919 AA 19990527 CA 1998-2309919 19981113  
 EP 1030675 A2 20000830 EP 1998-960199 19981113  
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,  
 IE, FI  
 JP 2001523645 T2 20011127 JP 2000-520800 19981113  
 US 2001048921 A1 20011206 US 1998-191970 19981113  
 PRAI US 1997-73230P P 19971114  
 WO 1998-US24209 W 19981113  
 AB The inventors have discovered that hematol. disorders, e.g., both  
 neoplastic (hematol. cancers) and non-neoplastic conditions, can be  
 treated by the induction of mixed chimerism using myeloreductive, but not  
 myeloablative, conditioning. Methods of the invention reduce GVHD  
 , esp. GVHD assocd. with mismatched **allogeneic** or  
 xenogeneic donor tissue, yet provide, for example, significant  
 graft-vs.-leukemia (GVL) effect and the like. The method comprises  
 administration of myeloreductive treatment (such as immunosuppressant  
 regimen), introduction of **allogeneic** donor **hematopoietic**  
 stem cell to form chimeric bone marrow in the recipient, and an  
 immunosuppressant regimen after donor stem cell introduction to prevent  
**graft-vs.-host** response. The immunosuppressant regimen  
 includes depletion of host **T lymphocytes** and/or NK  
 cells by treating with anti-CD4 or CD8 antibodies, anti-thymocyte  
 globulin, anti-lymphoblast globulin, thymic irradiation, and cytoreductive  
 agents (e.g. alkylating agents, alkyl sulfonates, nitrosoureas, triazenes,  
 antimetabolites, pyrimidine or purine analogs, vinca alkaloids,  
 epipodophyllotoxins, antibiotics, and others).  
 ST hematol disorder cancer immunosuppressant stem cell transplant  
 IT Histocompatibility antigens  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (HLA, class II; immunosuppressant regimen and **allogeneic** or  
 xenogeneic **hematopoietic** stem cell transplantation for  
 treatment of hematol. disorders)  
 IT Histocompatibility antigens  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (HLA-A; immunosuppressant regimen and **allogeneic** or  
 xenogeneic **hematopoietic** stem cell transplantation for  
 treatment of hematol. disorders)  
 IT Histocompatibility antigens  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (HLA-B; immunosuppressant regimen and **allogeneic** or  
 xenogeneic **hematopoietic** stem cell transplantation for  
 treatment of hematol. disorders)  
 IT Histocompatibility antigens  
 RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL  
 (Biological study); PROC (Process)  
 (HLA-DR; immunosuppressant regimen and **allogeneic** or  
 xenogeneic **hematopoietic** stem cell transplantation for  
 treatment of hematol. disorders)  
 IT Histocompatibility antigens

- RL: BPR (Biological process); BSU (Biological study, unclassified); BIOL (Biological study); PROC (Process)  
(HLA; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Erythrocyte  
(abnormalities; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Leukemia  
(acute myelogenous; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Sulfonates  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(alkanesulfonates; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT **Transplant and Transplantation**  
(**allotransplant**; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Nutrients  
(anti-; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Anemia (disease)  
(aplastic; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT **Transplant and Transplantation**  
**Transplant and Transplantation**  
(bone marrow; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Cord blood  
(cells; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Leukemia  
(chronic lymphocytic; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Leukemia  
(chronic myelocytic; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT **T cell (lymphocyte)**  
(depletion; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Blood  
(disease; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Immunity  
(disorder, inherited; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT **Lymphoblast**  
(globulin; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)

- IT **Transplant and Transplantation**  
 (graft-vs.-host reaction; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Leukemia  
 (graft-vs.-leukemia; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Lymphoma  
 (graft-vs.-lymphoma; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Neoplasm  
 (hematol.; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Alkylating agents, biological  
 Antibiotics  
 Hodgkin's disease  
**Immunosuppressants**  
 Multiple myeloma  
 Myelodysplastic syndromes  
 Sickle cell anemia  
 Thalassemia  
 Thymus gland  
 (immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT CD4 (antigen)  
 CD8 (antigen)  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Antibodies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Leukemia  
 (lymphocytic; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Hemoglobins  
 RL: ADV (Adverse effect, including toxicity); BSU (Biological study, unclassified); BIOL (Biological study)  
 (metabolic disorders, hemoglobinopathy; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Antibodies  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (monoclonal, OKT3 and LO-CD2a and others; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Lymphocyte  
 (natural killer cell, depletion; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Lymphoma  
 (non-Hodgkin's; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)


- IT Blood cell  
(peripheral; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Chemotherapy  
(refractory; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT **Hematopoietic precursor cell**  
(stem, transplant; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Radiation  
(thymic; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Globulins, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(thymocyte or lymphoblast; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Thymus gland  
(thymocyte, globulin; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Bone marrow  
Bone marrow  
Leukocyte  
(transplant; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT Alkaloids, biological studies  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(vinca; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT **Transplant and Transplantation**  
(xenotransplant; immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT 4375-07-9, Epipodophyllotoxin  
RL: BSU (Biological study, unclassified); BIOL (Biological study)  
(immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of hematol. disorders)
- IT 50-18-0, Cyclophosphamide 50-76-0, Dactinomycin 51-21-8, Fluorouracil 51-75-2, Mechlorethamine 52-24-4, Thiotepa 55-86-7D, Nitrogen mustard, derivs. 55-93-6, Dimethyl myleran 55-98-1, Busulphan 57-22-7, Vincristine 59-05-2, Methotrexate 59-30-3D, Folic acid, derivs. 120-73-0D, Purine, derivs. 147-94-4, Cytarabine 148-82-3, Melphalan 154-42-7, Thioguanine 154-93-8, Carmustine 289-95-2D, Pyrimidine, derivs. 305-03-3, Chlorambucil 488-41-5 865-21-4, Vinblastine 1404-00-8, Mitomycin 4342-03-4, Dacarbazine 11056-06-7, Bleomycin 13010-20-3D, Nitrosourea, derivs. 13010-47-4, Lomustine 13909-09-6, Semustine 15056-34-5D, Triazene, derivs. 18378-89-7, Plicamycin 18883-66-4, Streptozotocin 20830-81-3, Daunorubicin 21679-14-1, Fludarabine 23214-92-8, Doxorubicin 29767-20-2, Teniposide 31441-78-8, Mercaptopurine 33419-42-0, Etoposide 53643-48-4, Vindesine 58957-92-9, Idarubicin 89149-10-0, Deoxyspergualin  
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
(immunosuppressant regimen and **allogeneic** or xenogeneic **hematopoietic** stem cell transplantation for treatment of

hematol. disorders)  
 IT 154-42-7, Thioguanine 21679-14-1,  
 Fludarabine  
 RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)  
 (immunosuppressant regimen and **allogeneic** or xenogeneic  
**hematopoietic** stem cell transplantation for treatment of  
 hematol. disorders)  
 RN 154-42-7 HCAPLUS  
 CN 6H-Purine-6-thione, 2-amino-1,7-dihydro- (9CI) (CA INDEX NAME)



RN 21679-14-1 HCAPLUS  
 CN 9H-Purin-6-amine, 9-.beta.-D-arabinofuranosyl-2-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




L77 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2002 ACS  
 AN 1986:602908 HCAPLUS  
 DN 105:202908  
 TI Prevention of **graft-versus-host** disease in  
**allogeneic** bone marrow transplantation by pretreatment with 2'-  
**deoxycoformycin**  
 AU Epstein, Joshua; Bealmear, Patricia M.; Kennedy, David W.; Herrmann,  
 Michael J.; Islam, Anwarul; Wiedl, Sheila C.  
 CS Dep. Med. Oncol., Roswell Park Mem. Inst., Buffalo, NY, USA  
 SO Exp. Hematol. (N. Y.) (1986), 14(9), 845-9  
 CODEN: EXHMA6; ISSN: 0301-472X  
 DT Journal  
 LA English  
 CC 1-7 (Pharmacology)  
 AB Germ-free mice were used as a model for acute **graft-vs.-**  
**host** disease (GVHD) in **allogeneic** bone marrow  
 transplantation (BMT). C3H/He recipients of DBA/2 cells showed typical  
 symptoms of acute GVHD and died within 8 days. Incubation of the cells  
 with 1 .mu.M 2'-**deoxycoformycin** (2dCF) [53910-25-1]  
 (an adenosine deaminase inhibitor) plus 100 .mu.M deoxyadenosine (dAdo)  
 [958-09-8] for 1 h inhibited all **T-cell** functions as  
 well as **T-cell**-dependent B-cell functions, but had no  
 effect on B-cell functions that are **T-cell** independent

nor on the hemopoietic stem cells. Recipients of **allogeneic** cells that had been incubated with 2dCF + dAdo for 1 h prior to inoculation showed no signs, gross or histol., of acute or chronic GVHD up to 15 mo after transplantation. The recovery patterns of the blood and bone marrow were not affected by the treatment and were similar to those of recipients of treated and untreated syngeneic cells.

- ST **graft host disease deoxycoformycin; bone**  
marrow transplant **deoxycoformycin**
- IT Lymphocyte  
(function of, inhibition of, by **deoxycoformycin**, in  
**graft-vs.-host** reaction prevention)
- IT **Transplant and Transplantation, animal**  
(**graft-vs.-host** reaction, in  
bone marrow transplantation, **deoxycoformycin** inhibition of)
- IT Bone marrow  
(transplant, **graft-vs.-host** reaction in,  
**deoxycoformycin** inhibition of)
- IT 958-09-8  
RL: BIOL (Biological study)  
(**graft-vs.-host** reaction prevention by  
**deoxycoformycin** and)
- IT 53910-25-1  
RL: BIOL (Biological study)  
(**graft-vs.-host** reaction prevention by, in bone  
marrow transplantation)
- IT 53910-25-1  
RL: BIOL (Biological study)  
(**graft-vs.-host** reaction prevention by, in bone  
marrow transplantation)
- RN 53910-25-1 HCAPLUS
- CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-  
pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



- L77 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2002 ACS
- AN 1985:481417 HCAPLUS
- DN 103:81417
- TI Inhibition of adenosine deaminase and purine nucleoside phosphorylase and  
**T-cell** function in germfree mice and human peripheral  
blood
- AU Wiedl, Sheila C.; Bealmear, Patricia M.; Epstein, Joshua
- CS Dep. Dermatol., Roswell Park Mem. Inst., Buffalo, NY, 14263, USA
- SO Prog. Clin. Biol. Res. (1985), 181(Germfree Res.), 461-6  
CODEN: PCBRD2; ISSN: 0361-7742
- DT Journal
- LA English
- CC 1-7 (Pharmacology)
- AB Germ-free mice irradiated and given **allogeneic** bone marrow

transplants died after 8 days; however, 80% of the animals that received transplants treated with the adenosine deaminase [9026-93-1] inhibitor 2-**deoxycoformycin** [53910-25-1] (in combination with deoxyadenosine [958-09-8]) or the purine nucleoside phosphorylase [9030-21-1] inhibitor 8-aminoguanosine [3868-32-4] (in combination with 2'-deoxyguanosine [961-07-9]) survived for the 15-mo observation period with no gross symptoms of **graft-vs-host** disease.

Spleen cells from the 2'-**deoxycoformycin** group had no adenosine deaminase at 1 h and had regained 55.5% of normal activity by day 8 and 72.6% of normal activity by day 21. In in vitro expts., adenosine deaminase was absent for the entire 84 h culture period in the **deoxycoformycin**-treated cells, whereas pretreatment with 8-aminoguanosine and 2'-deoxyguanosine diminished but did not eliminate adenosine deaminase activity. The mixed lymphocyte reaction was inhibited by 92% by **deoxycoformycin**; in mitogen assays, phytohemagglutinin-, concanavalin A-, and pokeweed mitogen-responding cells were inhibited, but the lysopolysaccharide-responding cells were not inhibited. When human peripheral blood lymphocytes were also pretreated with **deoxycoformycin** and deoxyadenosine for 1 h, both the phytohemagglutinin- and concanavalin A-responding cells were inhibited; adenosine deaminase activity was completely inhibited during the entire 84-h assay period. It appeared that both drug combinations had potential in preventing **graft-vs-host** disease in bone marrow transplant patients.

- ST **T lymphocyte** adenosine deaminase inhibitor; purine nucleoside phosphorylase inhibitor **lymphocyte**; **graft vs host** disease marrow transplant
- IT Bone marrow, composition  
Spleen, composition  
(adenosine deaminase of, nucleoside analogs inhibition of, of humans and lab. animals, **T-lymphocyte** response in relation to)
- IT **Transplant and Transplantation, animal**  
(of bone marrow, **graft-vs-host** disease treatment in, with nucleoside analogs, **T-lymphocytes** of humans and lab. animals response in relation to)
- IT **Lymphocyte**  
(**T-**, nucleoside analogs effect on function of, adenosine deaminase inhibition in, of humans and lab. animals, bone marrow transplant in relation to)
- IT **Transplant and Transplantation, animal**  
(**graft-vs.-host** reaction, treatment of, in bone marrow transplant, with nucleoside analogs, **T-lymphocytes** of humans and lab. animals response in relation to)
- IT Bone marrow  
(transplant, **graft-vs-host** disease treatment in, with nucleoside analogs, **T-lymphocytes** of humans and lab. animals response in relation to)
- IT 961-07-9  
RL: BIOL (Biological study)  
(**T-lymphocyte** function response to aminoguanosine and, adenosine deaminase inhibition in relation to, of humans and lab. animals, bone marrow transplant in relation to)
- IT 53910-25-1  
RL: BIOL (Biological study)  
(**T-lymphocyte** function response to deoxyadenosine and, adenosine deaminase inhibition in relation to, of humans and lab. animals, bone marrow transplantation in relation to)
- IT 958-09-8  
RL: BIOL (Biological study)  
(**T-lymphocyte** function response to **deoxycoformycin** and, adenosine deaminase inhibition in relation

to, of humans and lab. animals, bone marrow transplant in relation to)

IT 3868-32-4  
 RL: BIOL (Biological study)  
 (T-lymphocyte function response to deoxyguanosine  
 and, adenosine deaminase inhibition in relation to, of humans and lab.  
 animals, bone marrow transplantation in relation to)


IT 9030-21-1  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitor, aminoguanosine as, T-lymphocyte  
 function response to deoxyguanosine and, of humans and lab. animals,  
 bone marrow transplant in relation to)

IT 9026-93-1  
 RL: BSU (Biological study, unclassified); BIOL (Biological study)  
 (inhibitor, deoxycoformycin as, T-  
 lymphocyte function response to deoxyadenosine and, of humans  
 and lab. animals, bone marrow transplant in relation to)

IT 53910-25-1  
 RL: BIOL (Biological study)  
 (T-lymphocyte function response to deoxyadenosine  
 and, adenosine deaminase inhibition in relation to, of humans and lab.  
 animals, bone marrow transplantation in relation to)

RN 53910-25-1 HCAPLUS  
 CN Imidazo[4,5-d][1,3]diazepin-8-ol, 3-(2-deoxy-.beta.-D-erythro-  
 pentofuranosyl)-3,4,7,8-tetrahydro-, (8R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



=> fil biosis

FILE 'BIOSIS' ENTERED AT 16:35:46 ON 20 JUN 2002

COPYRIGHT (C) 2002 BIOLOGICAL ABSTRACTS INC.(R)

FILE COVERS 1969 TO DATE.

CAS REGISTRY NUMBERS AND CHEMICAL NAMES (CNs) PRESENT  
 FROM JANUARY 1969 TO DATE.

RECORDS LAST ADDED: 19 June 2002 (20020619/ED)

=> d all tot

L99 ANSWER 1 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

AN 2002:124851 BIOSIS

DN PREV200200124851

TI Method of allogeneic hematopoietic stem cell transplantation without graft  
 failure or graft vs. host disease.

AU Waller, E. K.

CS Atlanta, Ga. USA

ASSIGNEE: EMORY UNIVERSITY

PI US 5800539 Sept. 1, 1998  
SO Official Gazette of the United States Patent and Trademark Office Patents,  
(Sept. 1, 1998) Vol. 1214, No. 1, pp. 422.  
ISSN: 0098-1133.  
DT Patent  
LA English  
NCL 623011000  
CC Blood, Blood-Forming Organs and Body Fluids - General; Methods \*15001  
Immunology and Immunochemistry - General; Methods \*34502  
Anatomy and Histology, General and Comparative - Regeneration and  
Transplantation \*11107  
Cytology and Cytochemistry - General \*02502  
General Biology - Miscellaneous \*00532  
IT Major Concepts  
Blood and Lymphatics (Transport and Circulation); Cell Biology; General  
Life Studies; Immune System (Chemical Coordination and Homeostasis);  
Surgery (Medical Sciences)  
IT Miscellaneous Descriptors  
BIOTECHNOLOGY; DONOR SOURCE; RECONSTITUTING CELLS; TRANSPLANT

L99 ANSWER 2 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 2000:44783 BIOSIS  
DN PREV200000044783  
TI Unrelated donor marrow transplantation using a preparative regimen of  
fractionated TBI, thiotepa, **fludarabine**, and ATG.  
AU Langston, A. A. (1); Redei, I. (1); Bucur, S. (1); Allen, A. (1); Cherry,  
J. K. (1); Bartlett, V. (1); **Waller, E. K. (1)**  
CS (1) Bone Marrow and Stem Transplant Center, Emory University, Atlanta, GA  
USA  
SO Blood, (Nov. 15 ) Vol. 94, No. 10 SUPPL. 1 PART 2, pp. 392b.  
Meeting Info.: **Forty-first Annual Meeting of the American Society of  
Hematology** New Orleans, Louisiana, USA December 3-7, 1999 The  
American Society of Hematology  
. ISSN: 0006-4971.  
DT **Conference**  
LA English  
CC Neoplasms and Neoplastic Agents - General \*24002  
Biochemical Studies - General \*10060  
Anatomy and Histology, General and Comparative - Regeneration and  
Transplantation \*11107  
Pathology, General and Miscellaneous - Diagnostic \*12504  
Blood, Blood-Forming Organs and Body Fluids - General; Methods \*15001  
Pharmacology - General \*22002  
Pathology, General and Miscellaneous - Therapy \*12512  
General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520

BC Hominidae 86215  
IT Major Concepts  
Hematology (Human Medicine, Medical Sciences); Oncology (Human  
Medicine, Medical Sciences); Pharmacology  
IT Diseases  
leukemia: blood and lymphatic disease, neoplastic disease  
IT Chemicals & Biochemicals  
ATG: antineoplastic - drug; **fludarabine**: antineoplastic -  
drug; thiotepa: antineoplastic - drug  
IT Alternate Indexing  
Leukemia (MeSH)  
IT Methods & Equipment  
bone marrow transplantation: therapeutic method, transplantation  
method, unrelated donor; fractionated TBI [fractionated total body  
irradiation]: radiologic method, therapeutic method  
IT Miscellaneous Descriptors  
Meeting Abstract

ORGN Super Taxa  
     Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
 ORGN Organism Name  
     human (Hominidae): patient  
 ORGN Organism Superterms  
     Animals; Chordates; Humans; Mammals; Primates; Vertebrates  
 RN 21679-14-1 (FLUDARABINE)  
     52-24-4 (THIOTEPA)

L99 ANSWER 3 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 1999:254095 BIOSIS  
 DN PREV199900254095  
 TI Allogeneic blood stem cell transplantation from unrelated donors after  
     nonmyeloablative conditioning therapy.  
 AU Bornhaeuser, M.; Neubauer, A.; Thiede, C.; Naumann, R.; Ritter, M.;  
     Geissler, G.; Freiberg-R., J.; Platzbecker, U.; Brendel, C.; Mohr, B.;  
     Ehninger, G.  
 CS Dep. Intern. Med. I, Univ. Hosp. Carl Gustav Carus, Dresden Germany  
 SO Annals of Hematology, (1999) Vol. 78, No. SUPPL. 2, pp. S50.  
     Meeting Info.: **International Symposium on Acute Leukemias VIII:  
     Prognostic Factors and Treatment Strategies** Muenster, Germany  
     February 27-March 3, 1999  
     ISSN: 0939-5555.  
 DT **Conference**  
 LA English  
 CC Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy \*24008  
     **Anatomy and Histology, General and Comparative - Regeneration and  
     Transplantation \*11107**  
     Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies \*15004  
     Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and  
     Reticuloendothelial Pathologies \*15006  
     Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and  
     Reticuloendothelial System \*15008  
     Pharmacology - Clinical Pharmacology \*22005  
     Pharmacology - Blood and Hematopoietic Agents \*22008  
     Pharmacology - Immunological Processes and Allergy \*22018  
     Neoplasms and Neoplastic Agents - Immunology \*24003  
     Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms  
     \*24010  
     Immunology and Immunochemistry - Immunopathology, Tissue Immunology  
     \*34508  
     **General Biology - Symposia, Transactions and Proceedings of  
     Conferences, Congresses, Review Annuals \*00520**  
     Cytology and Cytochemistry - Human \*02508  
     Genetics and Cytogenetics - Human \*03508  
     Biochemical Studies - General \*10060  
     Biochemical Studies - Nucleic Acids, Purines and Pyrimidines \*10062  
     Biochemical Studies - Proteins, Peptides and Amino Acids \*10064  
     Biochemical Studies - Carbohydrates \*10068  
     Pathology, General and Miscellaneous - Therapy \*12512  
     Blood, Blood-Forming Organs and Body Fluids - General; Methods \*15001  
 BC Hominidae 86215  
 IT Major Concepts  
     Oncology (Human Medicine, Medical Sciences)  
 IT Diseases  
     acute lymphoblastic leukemia: blood and lymphatic disease, treatment,  
     neoplastic disease; acute myeloid leukemia: blood and lymphatic  
     disease, treatment, neoplastic disease; chronic myeloid leukemia: blood  
     and lymphatic disease, neoplastic disease, treatment  
 IT Chemicals & Biochemicals  
     antithymocyte globulin: antineoplastic - drug, combination therapy,  
     immunosuppressant - drug; busulfan: antineoplastic - drug, combination  
     therapy; **fludarabine**: antineoplastic - drug, combination

therapy  
IT Alternate Indexing  
Leukemia, Lymphocytic, Acute (MeSH); Leukemia, Myeloid (MeSH);  
Leukemia, Myeloid, Chronic (MeSH)  
IT Methods & Equipment  
allogeneic blood stem cell transplantation: transplantation method,  
unrelated donor cell use; nonmyeloablative conditioning therapy:  
therapeutic method  
IT Miscellaneous Descriptors  
**Meeting Abstract; Meeting Poster**  
ORGN Super Taxa  
Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
ORGN Organism Name  
human (Hominidae): patient  
ORGN Organism Superterms  
Animals; Chordates; Humans; Mammals; Primates; Vertebrates  
RN 55-98-1 (BUSULFAN)  
21679-14-1 (FLUDARABINE)

L99 ANSWER 4 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
AN 1999:189466 BIOSIS  
DN PREV199900189466  
TI Unrelated allogeneic blood stem cell transplantation after nonablative  
conditioning.  
AU Ehninger, G.; Neubauer, A.; Thiede, C.; Naumann, R.; Ritter, M.; Geissler,  
G.; Freiberg-R., J.; Platzbecker, U.; Brendel, C.; Mohr, B.; Bornhaeuser,  
M.  
CS Dep. Internal Med. I, Univ. Hosp. Carl Gustav Carus, Dresden Germany  
SO Annals of Hematology, (1999) Vol. 78, No. SUPPL. 2, pp. S20.  
Meeting Info.: **International Symposium on Acute Leukemias VIII:  
Prognostic Factors and Treatment Strategies** Muenster, Germany  
February 27-March 3, 1999  
ISSN: 0939-5555.  
DT **Conference**  
LA English  
CC Neoplasms and Neoplastic Agents - General \*24002  
Biochemical Studies - General \*10060  
**Anatomy and Histology, General and Comparative - Regeneration and  
Transplantation \*11107**  
Pathology, General and Miscellaneous - Diagnostic \*12504  
Pathology, General and Miscellaneous - Therapy \*12512  
Blood, Blood-Forming Organs and Body Fluids - General; Methods \*15001  
Pharmacology - General \*22002  
Immunology and Immunochemistry - General; Methods \*34502  
**General Biology - Symposia, Transactions and Proceedings of  
Conferences, Congresses, Review Annuals \*00520**  
BC Hominidae 86215  
IT Major Concepts  
Hematology (Human Medicine, Medical Sciences); Oncology (Human  
Medicine, Medical Sciences)  
IT Diseases  
leukemia: blood and lymphatic disease, diagnosis, treatment, neoplastic  
disease  
IT Chemicals & Biochemicals  
busulphan: immunosuppressant - drug; cyclosporine: immunosuppressant -  
drug; **fludarabine**: immunosuppressant - drug; methotrexate:  
immunosuppressant - drug; ATG [anti-T lymphocyte globulin]:  
immunosuppressant - drug  
IT Alternate Indexing  
Leukemia (MeSH)  
IT Methods & Equipment  
allogenic blood stem cell transplantation: nonablative conditioning,  
transplantation method

IT Miscellaneous Descriptors  
**Meeting Abstract**  
 ORGN Super Taxa  
     Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia  
 ORGN Organism Name  
     human (Hominidae): donor, recipient, patient  
 ORGN Organism Superterms  
     Animals; Chordates; Humans; Mammals; Primates; Vertebrates  
 RN 59865-13-3Q (CYCLOSPORINE)  
     63798-73-2Q (CYCLOSPORINE)  
     59-05-2 (METHOTREXATE)  
     55-98-1 (BUSULPHAN)  
     **21679-14-1 (FLUDARABINE)**

L99 ANSWER 5 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN **1996:450871 BIOSIS**  
 DN **PREV199699173227**  
 TI Irradiated allogeneic donor lymphocytes have an anti-leukemic effect in  
     mice without producing graft vs host disease.  
 AU **Waller, E. K.; Murray, T. W.; Boyer, M.**  
 CS Bone Marrow Transplant Leukemia Program, Dep. Med., Emory Univ., Atlanta,  
     GA USA  
 SO Experimental Hematology (Charlottesville), (1996) Vol. 24, No. 9, pp.  
     1092.  
     Meeting Info.: **25th Annual Meeting of the International Society for**  
     **Experimental Hematology** New York, New York, USA August 23-27, 1996  
     ISSN: 0301-472X.  
 DT **Conference**  
 LA English  
 CC **General Biology - Symposia, Transactions and Proceedings of**  
     **Conferences, Congresses, Review Annuals 00520**  
     Radiation - Radiation and Isotope Techniques \*06504  
     **Anatomy and Histology, General and Comparative - Regeneration and**  
     **Transplantation \*11107**  
     Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and  
     Reticuloendothelial System \*15008  
     Neoplasms and Neoplastic Agents - Immunology \*24003  
     Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy \*24008  
     Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms  
     \*24010  
     Immunology and Immunochemistry - Immunopathology, Tissue Immunology  
     \*34508

BC Hominidae 86215  
     Muridae \*86375

IT Major Concepts  
     Blood and Lymphatics (Transport and Circulation); Clinical Immunology  
     (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical  
     Sciences); Physiology; Radiology (Medical Sciences)

IT Miscellaneous Descriptors  
     ANTI-LEUKEMIC EFFECTS; BLOOD AND LYMPHATICS; BONE MARROW  
     TRANSPLANTATION; GRAFT-VS-HOST DISEASE; IMMUNE SYSTEM; IMMUNE SYSTEM  
     DISEASE; IMMUNOTHERAPY; IRRADIATED ALLOGENEIC DONOR LYMPHOCYTES;  
     **MEETING ABSTRACT**; PATIENT; THERAPEUTIC METHOD; TUMOR  
     BIOLOGY

ORGN Super Taxa  
     Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia; Muridae:  
     Rodentia, Mammalia, Vertebrata, Chordata, Animalia  
 ORGN Organism Name  
     human (Hominidae); mouse (Muridae)  
 ORGN Organism Superterms  
     animals; chordates; humans; mammals; nonhuman mammals; nonhuman  
     vertebrates; primates; rodents; vertebrates

- L99 ANSWER 6 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 1996:49963 BIOSIS  
 DN PREV199698622098  
 TI Allogeneic bone marrow transplantation across a major MHC barrier using T-cell depleted bone marrow in mice.  
 AU Waller, E. K. (1); Murray, T. W.  
 CS (1) Bone Marrow Transplant Program, Emory Univ Dep. Med., Atlanta, GA USA  
 SO Blood, (1995) Vol. 86, No. 10 SUPPL. 1, pp. 571A.  
 Meeting Info.: 37th Annual Meeting of the American Society of Hematology Seattle, Washington, USA December 1-5, 1995  
 ISSN: 0006-4971.  
 DT Conference  
 LA English  
 CC General Biology - Symposia, Transactions and Proceedings of Conferences, Congresses, Review Annuals 00520  
 Cytology and Cytochemistry - Animal \*02506  
 Anatomy and Histology, General and Comparative - Surgery \*11105  
 Anatomy and Histology, General and Comparative - Regeneration and Transplantation \*11107  
 Pathology, General and Miscellaneous - Necrosis 12510  
 Pathology, General and Miscellaneous - Therapy \*12512  
 Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies \*15004  
 Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies \*15006  
 Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System \*15008  
 Bones, Joints, Fasciae, Connective and Adipose Tissue - Physiology and Biochemistry 18004  
 Immunology and Immunochemistry - Immunopathology, Tissue Immunology \*34508  
 BC Muridae \*86375  
 IT Major Concepts  
 Blood and Lymphatics (Transport and Circulation); Cell Biology; Immune System (Chemical Coordination and Homeostasis); Pathology; Physiology; Surgery (Medical Sciences)  
 IT Miscellaneous Descriptors  
 GRAFT FAILURE; GRAFT-VS.-HOST DISEASE; MAJOR HISTOCOMPATIBILITY COMPLEX MISMATCHING; MEETING ABSTRACT; MEETING POSTER; SURVIVAL  
 ORGN Super Taxa  
 Muridae: Rodentia, Mammalia, Vertebrata, Chordata, Animalia  
 ORGN Organism Name  
 Muridae (Muridae)  
 ORGN Organism Superterms  
 animals; chordates; mammals; nonhuman vertebrates; nonhuman mammals; rodents; vertebrates
- L99 ANSWER 7 OF 7 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.  
 AN 1996:49247 BIOSIS  
 DN PREV199698621382  
 TI Risk factors for severe acute renal failure (ARF) after matched unrelated donor transplantation (MUDT).  
 AU Redei, S.; Geller, R. B.; Devine, S.; O'Toole, K.; Persons, L.; Holland, H. K.; Connaghan, G.; Fleming, W. H.; Heffner, L. T.; Hillyer, C.; Waller, E. K.; Winton, E. F.; Wingard, J. R.  
 CS Emory Univ., Atlanta, GA USA  
 SO Blood, (1995) Vol. 86, No. 10 SUPPL. 1, pp. 391A.  
 Meeting Info.: 37th Annual Meeting of the American Society of Hematology Seattle, Washington, USA December 1-5, 1995  
 ISSN: 0006-4971.  
 DT Conference  
 LA English  
 CC General Biology - Symposia, Transactions and Proceedings of

**Conferences, Congresses, Review Annuals 00520**

Cytology and Cytochemistry - Human 02508

Biochemical Studies - Vitamins 10063

Biochemical Studies - Proteins, Peptides and Amino Acids 10064

**Anatomy and Histology, General and Comparative - Regeneration and Transplantation \*11107**

Pathology, General and Miscellaneous - Therapy \*12512

Blood, Blood-Forming Organs and Body Fluids - Blood Cell Studies \*15004

Blood, Blood-Forming Organs and Body Fluids - Blood, Lymphatic and Reticuloendothelial Pathologies \*15006

Blood, Blood-Forming Organs and Body Fluids - Lymphatic Tissue and Reticuloendothelial System \*15008

Urinary System and External Secretions - Pathology \*15506

Pharmacology - Clinical Pharmacology \*22005

Pharmacology - Blood and Hematopoietic Agents \*22008

Neoplasms and Neoplastic Agents - Therapeutic Agents; Therapy \*24008

Neoplasms and Neoplastic Agents - Blood and Reticuloendothelial Neoplasms \*24010

Immunology and Immunochemistry - Immunopathology, Tissue Immunology \*34508

BC Hominidae \*86215

IT Major Concepts

Blood and Lymphatics (Transport and Circulation); Clinical Immunology (Human Medicine, Medical Sciences); Hematology (Human Medicine, Medical Sciences); Oncology (Human Medicine, Medical Sciences); Pathology; Pharmacology; Physiology; Urology (Human Medicine, Medical Sciences)

IT Chemicals &amp; Biochemicals

METHOTREXATE

IT Miscellaneous Descriptors

ANTINEOPLASTIC-DRUG; BONE MARROW TRANSPLANTATION; COMPLICATION; HEMATOLOGIC MALIGNANCY; HLA CLASS I MISMATCH; **MEETING ABSTRACT; MEETING POSTER; METHOTREXATE; RISK FACTOR**

ORGN Super Taxa

Hominidae: Primates, Mammalia, Vertebrata, Chordata, Animalia

ORGN Organism Name

human (Hominidae)

ORGN Organism Superterms

animals; chordates; humans; mammals; primates; vertebrates

RN 59-05-2 (METHOTREXATE)

=&gt; fil medline

FILE 'MEDLINE' ENTERED AT 16:47:54 ON 20 JUN 2002

FILE LAST UPDATED: 19 JUN 2002 (20020619/UP). FILE COVERS 1958 TO DATE.

On June 9, 2002, MEDLINE was reloaded. See HELP RLOAD for details.

MEDLINE thesauri in the /CN, /CT, and /MN fields incorporate the MeSH 2002 vocabulary. Enter HELP THESAURUS for details.

THIS FILE CONTAINS CAS REGISTRY NUMBERS FOR EASY AND ACCURATE SUBSTANCE IDENTIFICATION.

=&gt; d all

L118 ANSWER 1 OF 1 MEDLINE

AN 2001119086 MEDLINE

DN 21063654 PubMed ID: 11122140

TI Short Report: Engraftment of T-cell-depleted allogeneic haematopoietic stem cells using a reduced intensity conditioning regimen.

AU Craddock C; Bardy P; Kreiter S; Johnston R; Apperley J; Marks D; Huber C;  
 Kolbe K; Goulding R; Lawler M; Goldman J; Hughes T; Derigs G  
 CS Department of Haematology, Queen Elizabeth Hospital, Birmingham, UK..  
 Charles.Craddock@university-b.wmids.nhs.uk  
 SO BRITISH JOURNAL OF HAEMATOLOGY, (2000 Dec) 111 (3) 797-800.  
 Journal code: 0372544. ISSN: 0007-1048.  
 CY England: United Kingdom  
 DT Journal; Article; (JOURNAL ARTICLE)  
 LA English  
 FS Priority Journals  
 EM 200102  
 ED Entered STN: 20010322  
 Last Updated on STN: 20010322  
 Entered Medline: 20010215  
 AB Graft-versus-host disease (GVHD) remains a significant complication in  
 patients undergoing allogeneic stem cell transplantation (SCT) using a  
 reduced intensity conditioning regimen. Although T-cell depletion (TCD)  
 reduces the risk of GVHD after a myeloablative conditioning regimen, it is  
 associated with an increased risk of graft failure. We have therefore  
 examined whether TCD compromises engraftment using a **fludarabine**  
 -based conditioning regimen. Fifteen patients have been transplanted using  
 such a regimen of whom 13 underwent ex vivo TCD. All but one patient  
 demonstrated durable engraftment and no patient receiving a TCD product  
 developed severe GVHD. Thus, TCD may play a role in GvHD prophylaxis using  
 such regimens.  
 CT Check Tags: Female; Human; Male  
 Adult  
 Aged  
 Graft vs Host Disease: MO, mortality  
 \*Graft vs Host Disease: PC, prevention & control  
 \*Hematopoietic Stem Cell Transplantation: MT, methods  
 \*Leukemia: SU, surgery  
 Lymphocyte Depletion: MT, methods  
 Middle Age  
 Multiple Myeloma: SU, surgery  
 \*T-Lymphocytes: IM, immunology  
 \*Transplantation Conditioning: MT, methods  
 Transplantation, Homologous

=> d his

(FILE 'HOME' ENTERED AT 15:18:35 ON 20 JUN 2002)  
 SET COST OFF

FILE 'REGISTRY' ENTERED AT 15:18:49 ON 20 JUN 2002

	E FLUDARABINE/CN
L1	1 S E3
	E PENTOSTATIN/CN
L2	1 S E3
	E 2CDA/CN
	E 2 CDA/CN
	E 2-CDA/CN
L3	1 S E3
	E 6-MP/CN
L4	1 S E3
	E 6-TG/CN
L5	1 S E3
	E GEMCITABINE/CN
L6	1 S E3
	E ARA-G/CN
	E 506U78/CN
	E 506 U78/CN

E 506-U78/CN  
E 2-AMINO-9-D-ARABINOSYL-6-METHOXY-9H-PURINE/CN  
E 2-AMINO-9-ARABINOSYL-6-METHOXY-9H-PURINE/CN  
E 9H-PURINE, 2-AMINO/CN  
E 9H-PURINE, 2-AMINO-6-METHOXY/CN  
L7 1 S E4

FILE 'HCAPLUS' ENTERED AT 15:30:12 ON 20 JUN 2002  
L8 482 S L1  
L9 624 S FLUDARABIN# OR NSC118218 OR NSC118218H OR NSC() (118218 OR 118  
L10 717 S L8,L9  
L11 605 S L2  
L12 186 S PENTOSTATIN#  
L13 547 S L3  
L14 589 S CLADRIBIN# OR CHLORODEOXYADENOSINE OR 2 CDA OR 2CDA  
L15 667 S DEOXYCOFORMYCIN#  
L16 2543 S L4  
L17 4029 S 6 MP OR MERCAPTOPYRINE  
L18 1271 S L5  
L19 2489 S THIOGUANINE OR 6 TG  
L20 854 S L6  
L21 1049 S GEMCITABIN#  
L22 34 S ARA G OR 506U78 OR 506 U78  
L23 14 S GUANINE ARABINOSIDE

FILE 'REGISTRY' ENTERED AT 15:34:03 ON 20 JUN 2002  
L24 1 S 38819-10-2

FILE 'HCAPLUS' ENTERED AT 15:34:42 ON 20 JUN 2002

FILE 'REGISTRY' ENTERED AT 15:35:22 ON 20 JUN 2002  
L25 1 S 121032-29-9

FILE 'HCAPLUS' ENTERED AT 15:36:00 ON 20 JUN 2002  
L26 19 S L25  
L27 11 S NELARABIN# OR NELZARABIN# OR GW 506789  
L28 106 S L24  
L29 8874 S L11-L23,L26-L28  
E TRANSPLANT/CT  
E E5+ALL  
L30 26426 S E7-E12,E6+NT  
E E41+ALL  
L31 3775 S E2  
L32 59 S L10 AND L30,L31  
L33 153 S L29 AND L30,L31  
E IMMUNOSUPPRESSANT/CT  
E IMMUNOSUPPRESSANT/CT  
E E6+ALL  
L34 12698 S E5  
E E9 ALL  
E IMMUNOSUPPRESS/CT  
E E8+ALL  
L35 11246 S E2+NT  
E E6+ALL  
L36 5372 S E3+NT  
L37 42 S L10 AND L34-L36  
L38 308 S L29 AND L34-L36  
L39 457 S L32,L33,L37,L38  
L40 51 S L39 AND ALLOGEN?  
L41 36 S L39 AND ALLOTRANS?  
L42 69 S L40,L41  
L43 58 S L39 AND HEMATOPO?  
E HEMATOPO/CT

```

                E E44+ALL
L44      21133 S E5+NT
L45      52 S L44 AND L39
L46      103 S L42,L43,L45
L47      4 S L46 AND NATURAL(L)KILLER(L)CELL
L48      26 S L46 AND T CELL
L49      17 S L46 AND LYMPHOCYT?(L)T
L50      4 S L46 AND MONONUCLEAR(L)CELL
L51      31 S L47-L50
L52      26 S GRAFT(S)HOST AND L46
L53      6 S CYTOMEGAL? AND L46
L54      2 S (HIV OR HUMAN(L)IMMUNODEFICIEN?(L)VIRUS OR IMMUNOCOMP?) AND L
L55      10 S (AIDS OR ACQUIR?(L)IMMUNODEFICIEN?(L)VIRUS?) AND L46
L56      1 S (HUMAN OR ACQUIR?) (L)IMMUNODEFICIEN?(L)SYNDROM? AND L46
L57      37 S L52-L56
L58      15 S L51 AND L57
                E WALLER E/AU
L59      45 S E3,E7,E11
                E HILLYER C/AU
L60      23 S E3-E5
                E ROBACK J/AU
L61      14 S E3-E6
L62      77 S L59-L61
L63      11 S L62 AND L30,L31,L34-L36
                SEL DN AN 7 L63
L64      1 S L63 AND E1-E3
L65      0 S L62 AND L10
L66      0 S L62 AND L29
L67      4 S L63 AND L44
L68      3 S L67 NOT FOSCARNET
L69      3 S L64,L68
                SEL DN AN 2 4 6 7 10 12 13 L58
L70      7 S L58 AND E4-E24
L71      10 S L69,L70
L72      73 S L32,L37
L73      24 S L72 AND (GVHD OR GRAFT(L)HOST(L)DISEASE)
L74      4 S L71 AND L73
L75      20 S L73 NOT L74
                SEL L75 DN AN 1 2 15
L76      3 S L75 AND E25-E31
L77      13 S L71,L76 AND L8-L23,L26-L76
                SEL HIT RN

```

FILE 'REGISTRY' ENTERED AT 16:17:36 ON 20 JUN 2002

L78 3 S E32-E34

FILE 'REGISTRY' ENTERED AT 16:17:53 ON 20 JUN 2002

FILE 'HCAPLUS' ENTERED AT 16:17:59 ON 20 JUN 2002

FILE 'BIOSIS' ENTERED AT 16:18:24 ON 20 JUN 2002

```

                E WALLER E/AU
L79      124 S E3,E7,E11
                E HILLYER C/AU
L80      114 S E3-E6
                E ROBACK J/AU
L81      34 S E3,E5,E8,E9
L82      320412 S 11107/CC
L83      60 S L79-L81 AND L82
L84      1985 S L10
L85      145 S L82 AND L84
L86      203 S L83,L85
L87      131 S L86 AND (00520/CC OR (CONFERENCE OR CONGRESS OR POSTER OR SYM

```

L88 12 S L87 NOT (00520/CC OR CONFERENCE/DT)  
 L89 119 S L87 NOT L88  
     SEL DN AN L89 9 31  
     SEL DN AN L89 9 31 32  
 L90 3 S E1-E10 AND L89  
 L91 29 S L79 AND L89  
     SEL DN AN 1 17 19 21 L91  
 L92 4 S L91 AND E11-E18  
 L93 6 S L90,L92  
 L94 72 S L86 NOT L87-L93  
 L95 10 S L94 NOT AB/FA  
 L96 1 S L94 AND \*02502/CC AND \*34502/CC  
 L97 1 S L94 AND 02502/CC AND 34502/CC  
 L98 1 S L94 AND 02502/CC  
 L99 7 S L93,L96-L98

FILE 'BIOSIS' ENTERED AT 16:35:46 ON 20 JUN 2002

FILE 'MEDLINE' ENTERED AT 16:36:04 ON 20 JUN 2002

    E TRANSPLANTATION/CT  
     E E3+ALL  
 L100 250014 S E3+NT  
 L101 106114 S E43+NT  
 L102 79195 S E45+NT  
 L103 28963 S E44+NT  
 L104 1183 S L10  
 L105 208 S L104 AND L100-L103  
 L106 18 S L105 NOT AB/FA  
     E TRANSPLANTATION CONDITIONING/CT  
     E E3+ALL  
 L107 1442 S E9+NT  
 L108 90 S L107 AND L104  
 L109 209 S L105,L108  
     E HEMATOPO/CT  
     E E62+ALL  
     E E2+ALL  
 L110 222129 S E9+NT  
 L111 13 S L109 AND L110  
     E NATURAL KILLER CELLS/CT  
     E E3 ALL  
     E NATURAL KILLER CELLS/CT  
     E E3+ALL  
     E E2+ALL  
 L112 18647 S E20+NT  
     E MONONUCLEAR CELL/CT  
     E E4+ALL  
     E E2+ALL  
 L113 389115 S E13+NT  
 L114 4 S L111 AND L112,L113  
 L115 9 S L111 NOT L114  
 L116 196 S L109 NOT L111,L114,L115  
 L117 30 S L112,L113,L114 AND L116  
     SEL DN AN 17 L117  
 L118 1 S L117 AND E1-E3

FILE 'MEDLINE' ENTERED AT 16:47:54 ON 20 JUN 2002